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1. Abstract 
DNA replication is a tightly regulated elementary process that ensures the exact duplication 
and transfer of genetic information to the next generation. However, a wide range of 
exogenous and endogenous genotoxic insults often impair the progression of a replication 
fork and give rise to a phenomenon termed as replicative stress. In such a scenario, it is 
imperative for cells to maintain their DNA integrity to prevent genomic instability that may 
lead to tumorigenesis. This is achieved by instigating the DNA damage response (DDR), a 
highly organized, enzyme-based signaling cascade. While the contribution of kinases in this 
network has been very well studied, less is known about the role of their negative regulators, 
the phosphatases, in the same. Hence, our studies were aimed at investigating the function 
of a dual-specificity phosphatase, MKP1 (alias DUSP1), in both DNA replication and DDR. 
Identified as a MAP kinase phosphatase, MKP1 preferentially de-phosphorylates and 
inactivates p38MAPK and JNK, and protects the cell from stress-induced apoptosis.  
Our studies show that MKP1 inhibition accumulates phospho H2AX (γH2AX) and activates 
the DDR, even in the absence of any exogenous DNA damage. This effect was attributed to 
a previously unknown role of MKP1 in regulating DNA replication. Using the DNA fiber assay, 
we could demonstrate impaired replication fork progression and reduced origin firing upon 
MKP1 inhibition. Moreover, in the presence of an external replicative stress stimulus, 
gemcitabine, MKP1 inhibition was able to further down-regulate the speed of progressing 
forks. Additional investigations identified the activation of checkpoint kinases, MK2 and ATM, 
to be responsible for mediating these replication fork defects. Besides this, prolonged 
inhibition or transient depletion of MKP1 led to a massive induction of apoptosis, indicating a 
crucial function of this phosphatase in cellular survival. Cell death was accompanied by the 
degradation of an anti-apoptotic protein, Mcl-1, in the MKP1 deficient cells. Furthermore, for 
the first time, we detected a physical interaction between these proteins in an in-vitro co-
immunoprecipitation assay.  
Taken together, our findings indicate that MKP1 is required for efficient DNA replication and 
cellular survival. Furthermore, this protective nature of MKP1 can be exploited by 
pharmacological antagonists in various cancers which over-express this phosphatase. Thus, 
we propose MKP1 as an attractive druggable target in cancer therapy, inhibition of which can 
enhance replicative stress and promote cell death. 
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2. Introduction 
Owing to the enormity of human genome, it is of utmost importance to ensure the faithful and 
complete replication of DNA, for an accurate transmission of genetic information to the next 
generation (Remus and Diffley 2009). A failure to do so, can damage DNA by introducing 
single strand nicks, double strand breaks or abnormal DNA structures (Jones and Petermann 
2012). These damages, if left unresolved can result in genomic instability and hence 
uncontrolled cellular proliferation; or in extreme cases, activate programmed cell death 
(Norbury and Zhivotovsky 2004). Nonetheless, cells have devised two intelligent strategies to 
combat this kind of situation: first, by ‘avoiding’ the occurrence of such an event by making 
certain that the parental DNA is replicated exactly once per cell cycle, thus, eliminating the 
production of spontaneous DNA damage arising due to over / under replication; and second, 
by initiating signaling responses often mediated by kinases, to arrest the cell cycle and repair 
damaged DNA when needed, thereby ‘overcoming’ the problem.  
Since not all studies are conducted using human cells as model systems, the following 
sections will give a brief description of DNA replication and its regulation under various 
stressful conditions, based on findings from Xenopus and mammalian systems. 
2.1 Ready, set and fire! : Initiating DNA replication  
Unlike in prokaryotes, where replication initiates at a fixed position on the DNA (originC or 
oriC), studies in metazoans revealed the existence of not one, but several such sites 
randomly distributed throughout the genome (Leonard and Mechali 2013). Strikingly, the 
metazoan ‘origins’ of replication - the sites where DNA starts to unwind, also lacked a strong 
consensus sequence when compared to its prokaryotic counterpart (Gilbert 2004, Machida, 
Hamlin et al. 2005). Additionally, in metazoans, concurrently firing adjacent origins are 
organized into groups called ‘replicon clusters’ (where a replicon is the size of DNA 
replicated by one origin), whose activation is spatio-temporally regulated. This regulation is 
thought to be largely dependent on the chromatin organization surrounding these clusters. 
While euchromatin is replicated early on in the S-phase due to its open, conducive 
environment; origins present in the unfavorable regions of heterochromatin fire during the 
later stages. Despite this distinction among origins, the requirement of initiator proteins to aid 
replication remains conserved throughout evolution (Jackson and Pombo 1998, Mendez and 
Stillman 2003, Gillespie and Blow 2010). 
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2.1.1 Are you licensed yet?: Forming the pre-Replicative Complex 
Even before DNA is duplicated, initiator proteins start assembling at the origins and ‘license’ 
DNA for replication during the late mitosis and G1 stage of cell cycle. This involves the 
concerted action of ORC (Origin Recognition Complex), Cdc6 (Cell division cycle 6) and 
Cdt1 (Chromatin licensing and DNA replication factor 1) to recruit the hexameric, ring shaped 
minichromosome maintenance2-7 complex (MCM2-7). Among these, ORC, a six subunit 
complex (also called ORC1-6), is responsible for recognizing and binding to the origins 
(Rowles, Chong et al. 1996, Mendez and Stillman 2000). Cdc6 and Cdt1, on the other hand 
are recruited to the DNA in an ORC-dependent manner (Lei and Tye 2001, Blow and 
Hodgson 2002).  
 
Figure 2.1 Formation of the pre-Replicative Complex. 
In the late mitosis and G1-phase of the cell cycle, initiator proteins including ORC, Cdc6 and Cdt1 are 
sequentially loaded on the origin(s) (marked in blue). Subsequently, the helicase, MCM2-7 complex is 
loaded, facilitated by its interaction with Cdt1. This forms the ‘pre-Replicative Complex’ (pre-RC) 
where the MCM2-7 complex is still inactive. Figure adapted with modifications from (Machida, Hamlin 
et al. 2005). 
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Further experiments conducted in Xenopus unveiled the presence of Cdc6 on the origin, to 
be a pre-requisite for Cdt1 activity (Tsuyama, Tada et al. 2005). This sequential binding of 
ORC, Cdc6 and Cdt1 is followed by the loading of MCM2-7 helicase, which is facilitated by 
its interaction with Cdt1 (Cook, Chasse et al. 2004). Moreover, ATP binding and hydrolysis 
by the AAA+ ATPase family proteins ORC and Cdc6 might provide the necessary energy to 
either assemble the six subunits of MCM on the origin or open the preformed MCM hexamer 
and clamp it around the DNA (Gillespie, Li et al. 2001, Mendez and Stillman 2003). This 
forms the pre-Replicative Complex (pre-RC); an inactive replication machinery, ready for 
activation in the S-phase.  
2.1.2 Pulling the trigger: A kinase mediated activation of pre-RC 
Even though all potential origin sites are licensed, not all licensed origins fire in one cell 
cycle. With no strict predilection, origin firing within replicon clusters seems to involve a 
substantial degree of stochasticity (i.e. randomness) (Lei and Tye 2001, Blow, Ge et al. 
2011). Upon the onset of S-phase, two Ser/Thr kinases, namely, Cdk2 (Cyclin dependent 
kinase 2) and Cdc7 (Cell division cycle 7), get activated by associating with their respective 
regulatory subunits cyclin E / cyclin A and ASK (Activator of S-phase Kinase or also called 
Dbf4). Besides cyclin binding, Cdk2 is phosphorylated at Thr 160 by CAK (Cdk Activating 
Kinase) and dephosphorylated at Thr 14 and / Tyr 15 by a dual specificity phosphatase, 
Cdc25A to achieve full activation. The inhibitory phosphorylation at Tyr 15 is added by a 
kinase, Wee1, which keeps the constitutively expressed Cdk2 inactive until an appropriate 
stimulus for entry to S-phase is received (Watanabe, Broome et al. 1995, Sørensen and 
Syljuåsen 2012). The occurrence of such post translational modifications for Cdc7 has not 
yet been thoroughly investigated. 
Once fully functional, these S-phase kinases together promote the phosphorylation of 
MCM2-7 complex. In particular, phosphorylation of various sites in the N-terminal region of 
MCM2 and MCM4 has been identified to assist replication initiation; either by increasing the 
ability to interact with and load the MCM helicase co-factor Cdc45, or by inducing a 
conformational change activating its helicase function (Montagnoli, Valsasina et al. 2006, 
Tsuji, Ficarro et al. 2006). Besides this, another adaptor protein, TOPBP1, interacts with and 
positions DNA polymerase, pol E, (and subsequently pol D) onto origins. This replication 
machinery thus assembled is called a ‘replisome’, which is active. Since every origin when 
fired emanates two replication forks moving away from each other (and the origin); two 
replisomes are assembled in the opposite orientation. As MCM propels along the helix, it 
utilizes the energy of ATP hydrolysis to unwind the parental DNA and in the process, 
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generates stretches of single stranded DNA (ssDNA) which serve as templates for DNA 
polymerases. In this manner, replication continues until it meets another fork and terminates.  
 
Figure 2.2 Events mediating the activation of pre-RC. 
Upon entry into S-phase, the pre-RC complex on the origins is activated. Cyclin/Cdk and Cdc7/Dbf4 
kinase complexes promote the phosphorylation and activation of MCM2-7 complex. This is followed by 
the loading of helicase co-factor Cdc45 and two other adaptor proteins, GINS and TOPBP1. This 
facilitates the loading of DNA polymerase and a ‘replisome’ is formed. The MCMs start unwinding the 
DNA and a replication bubble is formed. Replication then proceeds bi-directionally. In principle, two 
replisomes are required on one origin, only one is shown here for convenience. Figure adapted with 
modifications from (Machida, Hamlin et al. 2005). 
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It should be noted that additional factors such as GINS complex (required for holding Cdc45-
MCM together), RFC-PCNA (clamp loader–sliding clamp complex, for holding DNA 
polymerase onto the DNA), RPA (single strand DNA binding protein) and certain histone 
chaperones (for chromatin remodeling) also constitute an active part of the replisome, whose 
details are beyond the scope of this thesis. There might still be many other factors involved 
which are yet to be discovered (Iizuka and Stillman 1999, Kubota, Takase et al. 2003, Majka 
and Burgers 2004). 
2.2 Do it once and do it right: preventing re-replication 
When a new strand of DNA is being synthesized, a new origin is also in the making. Since 
MCM activity is indispensable for starting replication, origin re-firing is avoided by restricting 
the assembly and activation of pre-RC (and so MCM), in two non-overlapping phases of the 
cell cycle. In G1, MCM2-7 present on the origins is kept passive (inactive) due to low Cdk 
activity. Once cells enter S-phase, a fully functional Cdk2 not only activates MCMs and 
initiates DNA synthesis, but at the same time also prevents re-replication by inhibiting the 
loading of additional MCMs through inactivation of all the pre-RC components.  
Phosphorylation of Cdc6 by Cdk, followed by its proteasomal mediated degradation, is the 
major mechanism of restraining replication to one cycle in yeast. Contrastingly, mammalian 
Cdc6 when phosphorylated by cyclinA-Cdk2; is exported out of the nucleus in a Crm-1 
dependent manner (Saha, Chen et al. 1998, Petersen, Lukas et al. 1999). However, Coverly 
and co-workers later reported that free, phosphorylated Cdc6 falls prey to regulated 
proteolysis, an action which seems to require the activity of cyclinA-Cdk2 (Coverley, Pelizon 
et al. 2000).  
Interestingly, during S-phase, both human Orc1 (the largest subunit of ORC), and Cdt1 suffer 
the same fate as yeast Cdc6, i.e., poly-ubiquitination by SCF ubiquitin ligase and proteolytic 
destruction. More so, here Cdt1 is phosphorylated at its N-terminus and thus primed by 
Cdk2/Cdk4 for binding with the substrate recognition component of SCF, Skp2 (Mendez, 
Zou-Yang et al. 2002, Liu, Li et al. 2004). The role of Cdk2 for Orc1 in this context is still not 
well elucidated. Along the same lines, studies done in Chinese hamster cells disclosed the 
existence of an Orc1 cycle in S-to-M transition where Orc1 oscillated between mono/di- 
ubiquitinated (in S-phase) and de-ubiquitinated (in M-phase) states. This ubiquitination event 
led to its selective dissociation from chromatin and impaired re-incorporation into the ORC 
complex (Li and DePamphilis 2002).  
In metazoans, Cdt1 is subjected to a second level of regulation by the replication inhibitor, 
geminin, where Cdt1-MCM6 contact is blocked when Cdt1 binds to geminin (Yanagi, Mizuno 
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et al. 2002). A dimer by nature, geminin tethers the C-terminus of Cdt1 to its coiled coil 
central domain and in this way prevents the entry of MCM2-7 by steric hindrance (Lee, Hong 
et al. 2004). Geminin levels fluctuate through the cell cycle with its accumulation in the S, G2 
and M phases, consistent with the inhibition of Cdt1 observed herein. To allow the formation 
of pre-RC during G1, Cdt1 must be relieved from the clasp of geminin, a process made 
possible by the ubiquitin ligase, APC (Anaphase Promoting Complex) (McGarry and 
Kirschner 1998).  
 
Figure 2.3 Events preventing re-replication. 
The S-phase kinases complexes, apart from activating MCM complex, also phosphorylate and 
inactivate the components of the replisome to prevent re-firing of the origins. Cdt1 and Cdc6 are 
phosphorylated and marked for proteasomal degradation. Cdt1 is additionally inhibited when it binds 
to Geminin. Cdc6 is also exported out of the nucleus in a Crm-1 dependent manner. Orc is degraded 
as well, however the involvement of a phosphorylation is still not elucidated well. See text for more 
details. Figure adapted with modifications from (Machida, Hamlin et al. 2005). 
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Besides these aforementioned mechanisms, origins are also inactivated by the process of 
replication itself, a newly emerging concept based on research done in Xenopus, where, 
Cdt1 was degraded during DNA synthesis and not initiation (Arias and Walter 2005, Takeda, 
Parvin et al. 2005). These mechanisms work together to safeguard genomic integrity by 
confining DNA replication to once and only once per cell cycle. 
2.3 Replicative stress  
It is not always smooth sailing for a replication fork in the genome, encountering various 
impediments along the way. This can include a wide range of obstacles generated by 
endogenous or exogenous means. Endogenous obstacles may include - spontaneously 
occurring DNA damage in the form of chemically modified bases, broken DNA or abasic 
sites; difficult to replicate secondary structures; long tandem repeats and DNA bound 
proteins. Here, DNA damage is most likely generated due to reactive oxygen species, 
reactive carbonyl species etc. which are common by products of cellular metabolic pathways 
(De Bont and van Larebeke 2004). On the other hand, various exogenous insults such as 
ultraviolet and ionizing irradiation, nucleoside analogs and topoisomerase inhibitors; can also 
contribute to the DNA damage (Espinosa, Zamora et al. 2003, Herrlich, Karin et al. 2008). 
Under such circumstances, the replisome does not move further and instead comes to a 
temporary halt. This results in replication fork stalling, until the barrier is eliminated. However, 
in certain cases, when a fork remains stalled for a long time, the replication machinery can 
get inactivated or fall off the DNA, giving rise to a collapsed fork, which is unable to restart 
even after the blockade is removed. The precise signaling mechanisms which help cells to 
deal with such stalling induced replicative stress constitute the replication checkpoint, 
explained in detail below (Bartek, Lukas et al. 2004, Zeman and Cimprich 2014). 
2.4 Replication Checkpoint: ‘Check’mating DNA damage at the fork 
Cellular DNA can be damaged during any phase of the cell cycle by various agents (see 2.3). 
To overcome this threat, cells elicit the DNA damage response (DDR) which is a complex set 
of signaling pathways orchestrated by various kinases like ATR, ATM, Chk1 and Chk2. 
Particularly during S-phase, when replication fork progression is hampered, cells activate 
these kinases and induce the ‘replication checkpoint’ which constitutes a small branch of the 
DDR network. 
2.4.1 Switch on those kinases: Activating the ATM and ATR signaling 
When an ongoing replication fork meets an obstacle, DNA polymerases stall. Nevertheless, 
MCM helicases continue to move forward and unwind the double helix, leaving behind long 
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stretches of single stranded DNA (ssDNA) that immediately get coated by RPA (Replication 
Protein A) – a ssDNA binding protein (Walter and Newport 2000, Byun, Pacek et al. 2005). 
This sends a signal to the upstream nuclear phosphatidylionositol-3 (PI-3) like Ser/Thr kinase 
– ATR (ATM (ataxia telangiectasia mutated)-and Rad3-related), which places itself onto the 
stalled forks by interacting with its DNA bound partner protein, ATRIP (ATR Interacting 
Protein). This is followed by phosphorylation of ATR at Thr 1989 and recruitment of various 
accessory proteins like Rad17, Claspin and the 9-1-1 complex, all of which are required for 
complete activation of the ATR signaling pathway (Parrilla-Castellar, Arlander et al. 2004, 
Branzei and Foiani 2009).  
Still another nuclear transducer kinase, ATM (Ataxia Telangiectasia Mutated), commonly 
known as a DNA double strand break (DSB) responsive kinase, also becomes activated by 
ATR after replication fork blocks (Stiff, Walker et al. 2006). Functioning parallel to ATR, ATM 
– a dimer in unstressed conditions, gets auto-phosphorylated at Ser 1981 and dissociates 
into active monomers (Bakkenist and Kastan 2003). This requires the presence of various 
adaptor proteins including the MRN complex (MRE11-RAD50-NBS1), 53BP1 (p53-Binding 
Protein1) and MDC1 (Mediator of DNA damage Checkpoint 1) at the fork. It should be noted 
here that the mechanisms underlying the activation of ATR and ATM are still not thoroughly 
understood. Once activated, ATR majorly targets Checkpoint kinase 1 (Chk1) for 
phosphorylation at Ser 317 and Ser 345, whereas Checkpoint kinase 2 (Chk2) is 
phosphorylated by ATM at Thr 68 (Zhao and Piwnica-Worms 2001, Kastan and Bartek 
2004). These checkpoint kinases phosphorylate and inactivate the Cdc25 phosphatases, 
thereby arresting the cell cycle via inhibition of Cdk-cyclin activity (Bartek and Lukas 2003, 
Reinhardt and Yaffe 2009).  
Besides Chk1 and Chk2, ATM and ATR phosphorylate and activate many other proteins 
including some important ones like p53 and H2AX (Histone 2AX). The transcription factor 
p53, upon phosphorylation and activation, up-regulates a cyclin-Cdk inhibitor p21, and 
mediates cell cycle arrest at the G1/S transition. p53 is also known to facilitate apoptosis 
under conditions of extreme stress, for e.g., by increasing transcription of pro-apoptotic 
proteins (Zilfou and Lowe 2009).  
On the other hand, the histone H2A variant, H2AX, is phosphorylated in its C-terminal tail at 
Ser 139, in response to DNA damage. Initially this phospho H2AX, is localized to the site of 
DNA damage, but later spreads to approximately 50 kb on either sides of the damage. H2AX 
not only marks the sites of stalled replication and DNA double strand breaks, but is also 
required for the recruitment of various proteins involved in DNA repair (Rogakou, Pilch et al. 
1998, Ward and Chen 2001, Thiriet and Hayes 2005, Ewald, Sampath et al. 2007).  
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Figure 2.4 Activation of replication checkpoint signaling. 
In the presence of an obstacle on the DNA template, DNA polymerase stalls. However, the MCM 
complexes continue to unwind the DNA and leave long stretches of ssDNA behind them. RPA coats 
these ssDNA which serves as a trigger for the checkpoint response. Various kinases including ATR 
(primarily), ATM and p38 are activated which phosphorylate and activate their downstream checkpoint 
kinases Chk1, Chk2 and MK2. These effector kinases bring about cell cycle arrest, DNA repair or 
apoptosis. ATM gets activated additionally by DNA DSBs. Not all phosphorylations are shown in this 
figure. See text for more details. Figure adapted with modifications from (Jones and Petermann 2012). 
2.4.2 Three’s company: p38-MK2 joins the DDR network 
In addition to the canonical ATR-Chk1 and ATM-Chk2 signaling pathways, the p38MAPK-
MK2 pathway has recently been identified within the DDR network (Bulavin, Higashimoto et 
al. 2001,Manke, Nguyen et al. 2005, Reinhardt, Aslanian et al. 2007). In response to various 
stress conditions including hyperosmolar stress, TNF-α treatment and DNA damage; 
p38MAP kinase gets dually phosphorylated on the Thr 181 and Tyr 183 residues in the T-X-
Y motif, by its upstream MAPKKs, namely, MKK3 and MKK6 (Brancho, Tanaka et al. 2003). 
Once activated, p38MAPK phosphorylates a number of downstream substrates including 
several transcription factors like p53, ATF2 etc., and kinases like MK2, MSK1 etc. However, 
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one of the bona-fide substrates of p38MAPK is the kinase MAPKAPK2 alias MK2 (Mitogen 
Activated Protein Kinase Activated Protein Kinase 2), which gets activated when 
phosphorylated at Thr 334, and travels to the cytoplasm (Gaestel 2006). There MK2 
phosphorylates a variety of substrates including the heat shock protein 27 (Hsp27) and the 
Cdc25 phosphatases. Thus, by inactivating Cdc25s, MK2 arrests the cell cycle (in the S and 
G2/M phases) in response to various DNA damaging agents. It is due to this nature of MK2 
that it is also referred to as the ‘checkpoint kinase 3’ (Chk3) functioning parallel to Chk1 and 
Chk2 (Stokoe, Engel et al. 1992, Manke, Nguyen et al. 2005).  
Hence, after activation, ATR, ATM and p38MAPK phosphorylate a plethora of downstream 
substrates which inhibit further DNA replication to arrest the cell cycle for DNA repair, or 
initiate apoptosis in case of overwhelming DNA damage. The following sections will give a 
detailed description the role played by some of these pathways in mediating the above 
mentioned effects. 
2.4.3 Inhibit globally but activate locally: Regulating replication initiation after 
stress 
2.4.3.1 Checkpoint signaling inhibits unfired replication clusters 
Unlike their upstream activators which are restricted to the sites of DNA damage, Chk1 and 
Chk2 are highly mobile proteins which elicit a global response by relaying the signal from the 
nucleus to the entire cell. These Ser/Thr kinases phosphorylate the cell cycle regulatory dual 
specificity phosphatase, Cdc25A, and mark it for ubiquitin-mediated degradation. In the 
Xenopus system, this is further accompanied by a Chk1-mediated phosphorylation and 
activation of Wee1. Since Cdk2 activity requires an inactive Wee1 kinase and an active 
Cdc25A phosphatase, such an event results in the accumulation of a non-functional Cdk2, 
phosphorylated at Tyr 15 (Costanzo, Robertson et al. 2000, Falck, Mailand et al. 2001, 
Sorensen, Syljuasen et al. 2004). Along similar lines, in 2003, using Xenopus, Costanzo et 
al., reported the inactivation of Cdc7 kinase by ATR after topoisomerase inhibition 
(Costanzo, Shechter et al. 2003). Such a down regulation of Cdk2 and Cdc7 activity inhibits 
the helicase co-factor Cdc45, from loading onto origins, thus preventing origin firing from the 
‘unfired replicon clusters’ during replicative stress (Shechter, Costanzo et al. 2004, 
Syljuasen, Sorensen et al. 2005, Jones and Petermann 2012). In this manner, a negative 
regulation on replication initiation protects the ‘still-to-be-replicated’ parts of genome from 
instability or damage until the replicative stress is relieved (Ge and Blow 2010, McIntosh and 
Blow 2012). This is accompanied by an increased origin firing within the replicon clusters 
which are already engaged in replication, to prevent any instability that might arise due to 
incomplete replication of these clusters. This phenomenon is explained in detail below. 
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2.4.3.2 Dormant origin firing in active replicon clusters 
Replication is bi-directional with each fork requiring a replisome (see 2.1.2). Thus, in 
principle, two MCM complexes should be enough for firing one origin. However, studies have 
revealed that MCM’s are loaded in ~20 fold excess over the number of DNA bound ORC 
molecules (Hyrien, Marheineke et al. 2003). These excessive MCM complexes are 
distributed throughout the genome and license ‘additional’ sites on the DNA (origins) which 
have the potential to fire, but are kept dormant (inactive) by the mildly active ATR-Chk1 
signaling in an unperturbed S-phase. Such a checkpoint regulation is required to ensure an 
optimal number of active replication forks at a given time. This is essential because 
excessive origin firing can deplete cells of the necessary replication factors and result in fork 
stalling or DNA DSBs (Marheineke and Hyrien 2004, Machida, Hamlin et al. 2005). 
 
Figure 2.5 Dormant origin firing to promote replication under stress. 
If two converging replication forks (shown with green MCMs, top) in an active replicon cluster, meet an 
obstacle on their way such that they are stalled (middle), the dormant origin in between them, now 
fires to complete the replication (lower). This is mediated by checkpoint signaling, which 
simultaneously also ensures that the blockade is removed. See text for more details. Figure adapted 
with modifications from (Blow, Ge et al. 2011). 
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Under conditions of replicative stress, in active replicon clusters, two converging forks 
originating from adjacent origins may stall. In such a scenario, the ‘dormant origins’ present 
between them fire to complete replication (Woodward, Gohler et al. 2006, Ge, Jackson et al. 
2007, Ibarra, Schwob et al. 2008, Blow, Ge et al. 2011) The mechanisms regulating dormant 
origin firing are not yet well elucidated. Even though it could be purely stochastic, recent 
studies have identified an ATR-Plk1 (Polo-like kinase-1) dependent phosphorylation of Orc2 
(at Ser 188 in humans), to facilitate this process (Trenz, Errico et al. 2008, Song, Liu et al. 
2011). Thus, checkpoint signaling works to regulate replication initiation in times of stress by 
inhibiting replication cluster activation but activating dormant origin firing near stalled forks.  
2.4.4 Mending the ends: Repair and restart of stalled replication forks 
Regulating replication in the manner as described above is required to arrest cell cycle for 
repairing the damaged after replicative stress. When a progressing replisome comes across 
a single strand gap or a bulky lesion on the parental DNA; cells make use of identical sister 
chromatids generated during DNA replication and employ the homologous recombination 
pathway (HR) to repair the damage (Saintigny, Delacôte et al. 2001). A key player involved in 
this pathway is Rad51, which after binding to the 3’ single stranded overhangs or single 
stranded gaps, mediates homology search and promotes recombination into the homologous 
double stranded DNA (Sigurdsson, Van Komen et al. 2001). In case of DSBs generated at 
collapsed forks, HR needs the additional action of certain exonucleases like MRE11 (Meiotic 
Recombination 11) and EXO1 (Exonuclease 1) which assist the formation of 3’ overhangs. 
(Nimonkar, Genschel et al. 2011). Such a recombination promotes the restart of a stalled fork 
which requires several accessory proteins like PARP1, BRCA2, BRCA1 and the FA complex. 
PARP1 (Poly (ADP-ribose) polymerase 1) is recruited to aberrant DNA structures and single 
strand gaps where it assists the loading of MRE11 to create the 3’ overhangs, BRCA2 
(Breast-Cancer Susceptibility Gene 2) keeps this MRE11 mediated resection under check by 
preventing excessive nuclease activity. These aforementioned proteins along with other 
adaptor molecules perform many key functions during DNA repair, whose details are beyond 
the scope of this thesis. 
In addition to the above error-free repair pathway, an error-prone translesion synthesis (TLS) 
also exists which gives the cell an opportunity to switch its replicative DNA polymerase with a 
translesion polymerase (TLS polymerase). Such a polymerase is able to tolerate a variety of 
distortions in the DNA template and thus is able to replicate past these damages. The TLS 
polymerase switching requires the ubiquitin ligase Rad18 mediated mono-ubiquitination of 
PCNA as well (Hoege, Pfander et al. 2002, Prakash, Johnson et al. 2005, Jones and 
Petermann 2012). In addition to this, another level of regulation for TLS polymerases was 
shown in a recent study from Köpper et al., where the TLS polymerase activity was subjected 
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to negative regulation by the checkpoint kinase - MK2, in response to gemcitabine induced 
DNA damage. This study established a role of MK2 in regulating DNA replication and repair, 
in addition to controlling cell cycle progression (Kopper, Bierwirth et al. 2013).  
Apart from these specialized polymerases, cells also possess certain DNA helicases, namely 
BLM, WRN and FANCJ which exclusively unwind difficult-to-replicate secondary structures, 
thereby facilitating replisome progression. These helicases are also known to restart stalled 
forks by aiding HR. These processes are also thought to be dependent on the checkpoint, 
but their exact function in the same is still under investigation. 
Even though the replication checkpoint acts to safeguard the genome, still, under conditions 
of extreme replicative stress, cell death pathways are initiated. This is to prevent the 
accumulation of DNA damage or aberrant DNA structures which could give rise to mutations 
in the next generation. How does a cell activate these pathways? What are the proteins 
involved? These questions will be addressed briefly in the next section.  
2.5 Cell death by apoptosis 
Under conditions of extreme stress, cells activate a programmed set of signaling events to 
undergo death - a phenomenon referred to as apoptosis. This cellular suicide is 
accompanied by various morphological changes, most notably; membrane blebbing, 
chromatin condensation and DNA fragmentation (Kerr, Wyllie et al. 1972).  
Apoptosis can be triggered by both extrinsic and intrinsic stimuli. While extrinsic stimuli 
include death ligands (Fas-L or TNF-α) binding to cell surface receptors, intrinsic stimuli 
encompass various conditions of cellular stress (DNA damage, heat shock etc.) that result in 
a compromised mitochondrial membrane potential. Irrespective of the stimuli, apoptosis 
requires a specific class of enzymes called caspases (cysteine aspartic proteases) that have 
cysteine in their active site and cleave their target proteins at aspartic residues. Owing to 
their proteolytic nature, these enzymes exist in an inactive zymogenic form (pro-caspases) in 
healthy cells and undergo activation only when cleaved (Nicholson 1999).  
Caspases can be divided broadly into two categories based on their function: Initiator and 
Effector caspases. Initiator caspases are the upstream enzymes (Caspase 2, 8, 9, 10) that 
are brought together by certain adaptor proteins to form an aggregate. Such a complex 
formation stimulates the proteolytic activity of these enzymes, which subsequently cleave 
and activate their downstream targets - the effector caspases. The effector / executioner 
caspases (Caspase 3, 6, 7) chop down several cellular proteins. Some of the most important 
ones include: the nuclear lamins, whose cleavage leads to the breakdown of nuclear 
envelope; certain DNA repair proteins like PARP which get inactivated when cleaved; and 
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the inhibitor protein ICAD (Inhibitor of the Caspase-Activated-DNase) whose proteolytic 
cleavage frees the DNase, CAD (Sakahira, Enari et al. 1998). The DNA fragmented by this 
DNase is packaged along with other cleavage products into small vesicles called apoptotic 
bodies, that are phagocytized by macrophages, and thus cleared from the surroundings. In 
this manner, apoptosis presents itself as a clean mechanism to get rid of damaged cells, 
avoiding a spillover of toxic contents into the surroundings. (Elmore 2007, Taylor, Cullen et 
al. 2008). Since replicative stress is an intrinsic trigger for apoptosis, in the next sections, a 
concise description of the various proteins involved in the mammalian intrinsic apoptotic 
pathway will be given (Rich, Allen et al. 2000). 
Do you have the potential? Bcl2 family proteins in regulating mitochondrial 
membrane integrity and apoptosis 
Mitochondria play a key role in activating the intrinsic pathway of apoptosis that involves 
mitochondrial outer membrane permeabilization mediated by the Bcl2 family proteins. This 
releases cytochrome c from the inter-membrane space into the cytosol, where it interacts 
with APAF1 (Apoptotic Protease Activating Factor 1) to form a complex called the 
‘apoptosome’. Once assembled; the apoptosome recruits and activates the initiator pro-
caspase 9, thus commencing a chain of caspase events culminating in the activation of 
caspase 3 and caspase 7 (Chinnaiyan 1999, Saelens, Festjens et al. 2004, Riedl and 
Salvesen 2007).  
The mitochondrial Bcl2 (B-cell-lymphoma 2) family includes both pro-apoptotic and anti-
apoptotic proteins possessing BH domain (Bcl2 Homology domain). The anti-apoptotic family 
includes 5 members, namely Bcl-2-related gene A1 (A1), Bcl-2, Bcl-2-related gene long 
isoform (BCL-xL), BCL-w, and myeloid cell leukemia 1 (Mcl-1). Each of these anti apoptotic 
proteins contains four BH domains that mediate their interaction with their pro-apoptotic 
counterparts (Green and Evan 2002). This keeps all the pro-apoptotic proteins inactive until 
an appropriate signal is received. For example; Mcl-1 interacts with Bak, one of the effector 
pro-apoptotic protein, and keeps it in an inactive monomeric form under healthy conditions 
(Willis, Chen et al. 2005). 
On the other hand, the pro-apoptotic family is further sub-classified into BH3 only and 
effector proteins. The effector proteins include Bak and Bax (each having three BH domains) 
that homo-oligomerize and form pores in the outer mitochondrial membrane (OMM), thus 
disturbing OMM integrity and leading to mitochondrial outer membrane permeabilization 
(MOMP). The BH3 only proteins (Puma, Noxa, Bad, Bim etc.) have one BH domain (BH3), 
and act either as ‘activators’, ‘de-repressors’ or ‘sensitizers’, depending on their interaction 
with the various members of the Bcl-2 family. While ‘activators’ like Bid and Bim directly 
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interact with Bax/Bak and induce their oligomerization, promoting MOMP; de-repressors and 
sensitizers regulate the activity of anti-apoptotic proteins by inhibiting them. De-repressors 
and sensitizers act in the following manner: Anti-apoptotic proteins (e.g. Bcl2) remain bound 
to the direct activators (e.g. Bim) repressing their function under normal conditions. However, 
during cellular stress like DNA damage, the de-repressor BH3 family protein (e.g. Puma) 
gets induced and now competes with the direct activator for binding to the anti-apoptotic  
protein. In this manner, the direct activator is released and the anti-apoptotic protein is 
inhibited by BH3 only de-repressor. On the contrary, ‘sensitizers’ remain bound to the anti-
apoptotic proteins under normal and stressful conditions, thus keeping the direct activators 
uninhibited and free to promote MOMP. The same protein can function as a de-repressor or 
a sensitizer depending on the stimuli. In this manner, regulating the interaction among Bcl2 
family proteins is crucial for determining the survival outcome of a cell during various stress 
conditions including replicative stress (Chipuk, Moldoveanu et al. 2010).  
However, if a damaged cell evades apoptosis, it can accumulate genetic mutations that give 
it an uncontrolled capacity to proliferate, thereby leading to cancer development. The 
following section will shed some light on this. 
2.6 Cancer and chemotherapy: DNA replication as a double edged sword 
DNA replication is the basis of all life; the deregulation of which can generate mutations that 
result in uncontrolled cellular proliferation and thus tumor formation. According to the model 
presented by Hanahan and Weinberg in 2000, tumor cells need to acquire certain hallmarks 
to become cancerous. These are summarized as follows: sustained proliferative signaling, 
ability to evade growth suppressors, replicative immortality, potential to invade surrounding 
tissues and metastasize, capacity to induce angiogenesis and resist cell death (Hanahan and 
Weinberg 2000). In 2011, this picture was enlarged by the addition of certain emerging 
characteristics like the ability of cancer cells to evade the immune system and deregulate 
cellular metabolism (Hanahan and Weinberg 2011). Thus, cancer is a ‘disease of self’, where 
genetic changes caused by exogenous or endogenous agents are responsible for its 
manifestation. This has motivated a large part of the scientific community to focus its 
research on understanding the basic biology of cancer and develop drugs that could help 
treat it.  
Chemotherapy is one of the many lines of cancer treatment which uses chemical substances 
to kill rapidly proliferating cells. Based on their mode of action and chemical structure, 
chemotherapeutic agents are classified into various categories some of which include: 
microtubule and topoisomerase inhibitors, alkylating agents, antimetabolites, antifolates and 
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cytotoxic antibiotics (Malhotra and Perry 2003). Among these, some selected agents that act 
by inhibiting DNA replication and generating DNA damage are outlined below. 
Antimetabolites and Antifolates 
Antimetabolites and antifolates are drugs that directly inhibit DNA synthesis, albeit with 
different mechanisms of action. Antifolates like methotrexate inhibit the enzyme dihydrofolate 
reductase (DHFR), which is required for the production of folate coenzymes. Since these 
folates assist purine and pyrimidine biosynthesis, such a drug is able to inhibit the synthesis 
of DNA by disturbing the nucleoside pool balance. On the other hand, antimetabolites like 
gemcitabine (2', 2’-Difluoro-desoxycytidine) and cytarabine (1-β-D-Arabinofuranosylcytosine) 
mimic the naturally occurring nucleosides (in this case cytosine) and are falsely incorporated 
into the replicating DNA instead of its normal counterpart. In addition, some antimetabolites 
like gemcitabine are also able to inactivate the enzyme ribonucleotide reductase, thus, 
enhancing its ability to interfere with replication by depleting the cellular pools of dNTPs. 
These are also called S-phase specific drugs as they target only the cells which are actively 
engaged in duplicating their genome (Ewald, Sampath et al. 2008).  
Alkylating agents and platinum based drugs  
DNA can also be damaged by covalently linking an alkyl group to one of its bases, by agents 
like mechlorethamine, cyclophosphamide etc. or by crosslinking the bases with each other 
(inter-strand or intra-strand crosslink) using platinum-based drugs like cisplatin, carboplatin 
etc. Unlike the antimetabolites, these drugs act in all the phases of cell cycle (McClean, 
Costelloe et al. 1999, Kelland 2007). 
Topoisomerase inhibitors 
Topoisomerases are the enzymes required for relaxing negative and positive supercoils that 
are created ahead of the unwound DNA. Drugs targeting these enzymes can inhibit both 
DNA replication and transcription, and also induce DSBs. This is achieved either via blocking 
the activity of the enzyme, or increasing its levels on DNA, thereby creating an obstruction for 
the progressing fork. Examples include camptothecin, etoposide etc.  
Besides these, numerous other approaches are taken for treating cancer. These include 
surgical removal of the tumor, radiation therapy, chemotherapy using microtubule inhibitors, 
proteasome inhibitors and anthracyclines; hormonal and immunotherapy.  
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2.7 Chemoresistance and combination therapy 
Despite the presence of various chemotherapeutic agents, achieving effective treatment has 
become difficult due to drug resistance. This loss of sensitivity can be acquired during 
therapy or be intrinsically present before the start of a treatment regime. The most common 
reasons for chemoresistance include effective drug efflux, increased drug inactivation, 
efficient DNA repair mechanisms and increased ability to evade apoptosis. Whether intrinsic 
or acquired, in both cases, resistant cells often become insensitive to other lines of 
chemotherapy as well (Wilson, Longley et al. 2006). This raises the need for developing 
combination therapies that might help in chemosensitization. One such chemotherapy based 
combination regime makes use of small molecules to inhibit the proliferative MAPK signaling 
pathway, which is often deregulated in various cancers.  
MAPKs or mitogen activated protein kinases are Ser/Thr kinases that when activated, govern 
the cellular outcome to a variety of external stimuli including growth factors, cytokines and 
stress signals. The three major branches of MAPK signaling include - ERK (Extracellular 
signal Related Kinase), p38MAPK, and JNK (c-jun-N-terminal Kinase). ERK responds to 
growth signals and promotes proliferation; whereas p38MAPK and JNK are majorly activated 
during cellular stress and facilitate survival or apoptosis depending on the stimuli (Johnson 
and Lapadat 2002). Among these, the ERK signaling pathway has garnered a lot of attention 
from researchers due to its oncogenic potential, which has led to the development of several 
inhibitors against the EGFR-Raf-MEK-ERK pathway (Roberts and Der 2007). This further 
makes it an interesting target in combination therapies as well. A well-known example of 
such an inhibitor used in gemcitabine combination therapy is an EGFR inhibitor, erlotinib, 
which is FDA approved for the treatment of metastatic pancreatic cancer 
(http://www.cancer.gov/cancertopics/druginfo/fda-erlotinib-hydrochloride#Anchor-Pancreati-
44285) (Moore, Goldstein et al. 2007). Besides this, several other drugs like sofarenib 
(against EGFR), imatinib (Against Bcr-abl tyrosine kinase) are also been approved. Still 
many more are in the different stages of clinical trials. 
2.8 Mitogen activated protein kinase phosphatases (MKPs) 
Since MAPKs control cellular proliferation and stress response, monitoring their activity is 
extremely important to avoid any deregulation that might assist tumor formation. This 
regulation is made possible by phosphatases, which reverse the phosphorylation required for 
MAPK activity. In response to an appropriate stimulus, MAPK gets dually phosphorylated on 
both Thr and Tyr residues of its T-X-Y motif. This phosphorylation and activation is mediated 
by its upstream MAPK Kinase (MKK), which is in turn activated by MAPK Kinase Kinase 
(MKKK). However, this signal is subjected to negative regulation by MAPK phosphatases 
INTRODUCTION                                                                                                                    19 
 
(MKP). These enzymes belong to the family of dual specificity phosphatases, and are able to 
bind and dephosphorylate MAPKs on both the Thr and Tyr residues, thereby inhibiting the 
respective pathway (Dhillon, Hagan et al. 2007, Wu 2007). This makes the role of MKPs 
equally paramount not only in cancer development and progression, but also in 
chemotherapeutic response. 
The MKP family has eleven members, which share structural homology with each other. All 
of them possess a non-catalytic N-terminal domain which share homology with the Cdc25 
phosphatases; and a C-terminal catalytic domain that displays a sequence homology related 
to the VH-1 phosphatase encoded by the vaccinia virus.  Inspite of this structural similarity, 
MKPs are further sub-classified into three categories - Type I, Type II and Type III; 
depending on their substrate specificity and sub-cellular localization. The section below will 
focus on one of these MKPs, named MKP1 (Bermudez, Pages et al. 2010). 
2.8.1 Switching off the MAPK signaling by mitogen activated protein kinase 
phosphatase 1 (MKP1)  
MKP1 is the archetypal member of the MKP family. Originally discovered as a growth 
inducible nuclear phosphatase, MKP1 was later shown to be induced in response to a variety 
of stress stimuli including oxidative stress, heat shock and DNA damage (Keyse and Emslie 
1992, Alessi, Smythe et al. 1993, Liu, Gorospe et al. 1995). Using its N-terminal kinase 
interaction motif, MKP1 binds to its substrate and undergoes a conformational change that 
enhances its catalytic activity. Both in-vitro and cell culture approaches have identified 
p38MAPK and JNK (also called the stress activated protein kinases or SAPKs) as the 
preferential substrates of MKP1 (Slack, Seternes et al. 2001, Owens and Keyse 2007).  
 
Figure 2.6 A schematic depicting the role of MKP1.  
Upon receiving any kind of stress stimulus, like heat, osmotic stress, or even DNA damage, cellular 
stress response pathways are activated which include the p38MAPKs and JNKs. These kinases 
promote cell cycle arrest and apoptosis to combat the stress. However, a negative regulator of these 
kinases, a phosphatase MKP1 (alias DUSP1) is also activated which tries to balance this activating 
signal by dephosphorylating the p38MAPK and JNK on their T-X-Y motif. See text for more details.  
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Activated by its upstream kinase MKK4 and MKK7, JNK is known to regulate cell cycle 
progression and apoptosis in response to various stress stimuli, by phosphorylating a 
number of downstream targets including c-Jun (an active part of the transcription factor AP1), 
p53, and certain members of the Bcl2 family. A similar role is played by p38MAPK, which has 
been described in section 2.4.2. However, the effects of these kinases are largely dependent 
on the strength and kind of stimulus. A stronger stress stimulus leads to cell death while a 
milder one results in cell cycle arrest. (Davis 2000, Wagner and Nebreda 2009).  
Due to its ability to negatively regulate these MAPKs, the last decade has revealed an 
important role of MKP1 in cancer development, progression and chemoresistance. 
2.8.2 MKP1 in cancer and chemoresistance  
MKP1 has been extensively studied in human tumors, where an alteration of its expression 
pattern is observed. This is shown to be largely dependent on the grade and type of cancer.  
Breast, non-small cell lung and pancreatic carcinomas showed an increased expression of 
MKP1, while ovarian carcinoma showed a down-regulation of this protein. Furthermore, a 
fluctuation of MKP1 expression is observed within one type of cancer, with the lower grade 
carcinomas up-regulating MKP1 and the higher grade carcinomas showing a decrease in the 
expression. This kind of situation is most frequently observed in colon, prostate, bladder and 
liver carcinomas. Even though it is seemingly difficult to understand such an inconsistent 
expression pattern of MKP1, it is speculated that having lower levels of MKP1 facilitates 
proliferation by hyper-activating the ERK pathway, while an up-regulation is required to shut 
off the apoptotic SAPK pathways (Wu 2007, Boutros, Chevet et al. 2008). While these 
studies establish MKP1 as an important player in cancer development and progression, over-
expression of MKP1 has also been correlated with chemoresistance. In 1998, Franklin and 
co-workers reported a protective role for MKP1 in human leukemic cells against UV induced 
apoptosis (Franklin, Srikanth et al. 1998). Since then, many studies have been performed 
using various genotoxic agents, to evaluate MKP1 in mediating drug resistance. While an 
increased expression of MKP1 in NSCLC (Non-Small-Cell Lung Carcinoma) and 
osteosarcoma was responsible for cisplatin resistance due to an attenuated JNK signaling; 
MKP1-deficient MEFs were sensitized to anisomycin treatment, due to an active p38MAPK 
pathway (Wu and Bennett 2005, Chattopadhyay, Machado-Pinilla et al. 2006, Wang, Zhou et 
al. 2008). Furthermore, in breast cancers, MKP1 over-expression was shown to reduce the 
cytotoxic effects of doxorubicin, microtubule inhibitors and alkylating agents; by targeting the 
JNK pathway (Small, Shi et al. 2007). Taken together, these studies establish a key role of 
MKP1 in chemoresistance, making it an attractive candidate to research. 
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2.9 Scope of thesis 
As mentioned in the previous section, MKP1 plays a protective role in response to various 
phase unspecific DNA damaging agents, thus determining the outcome of these 
chemotherapeutic regimens. This nature of MKP1 motivated us to explore its function, 
specifically during conditions of replicative stress. Furthermore, as various checkpoint 
kinases remain active even during an unperturbed cell cycle to ensure efficient and faithful 
replication, we were keen to inspect the contribution of this phosphatase in unstressed 
conditions as well. These studies will add to our existing knowledge about phosphatases, 
particularly in the regulation of checkpoint signaling under replicative stress and normal 
conditions. 
In addition to the basic translational research, these investigations will also help to examine 
the relevance of MKP1 as a potential drug target to increase the sensitivity of cancer cells to 
S-phase targeting drugs. As reported by Köpper et al., the kinase MK2 of the p38/MK2 
pathway when inhibited protects cells from gemcitabine induced DNA damage. Thus, an 
activation of this kinase might sensitize tumor cells towards chemotherapy like gemcitabine. 
This makes it more interesting for us to study MKP1 and use inhibitors against it that might 
help increase the activity of p38/MK2 pathway and perhaps also lead to chemosensitization.  
With these ideas in mind, experiments were conducted to monitor checkpoint activation, 
replication dynamics and cellular survival, using a pharmacological inhibitor of MKP1, termed 
BCI, and a replicative stress agent, gemcitabine. We employed immunoblot assays to look 
for the activation of several DNA damage response and cellular survival/apoptosis markers. 
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3. Materials         
3.1 Technical Devices 
 
Blotting chamber  Biozym, Hessisch Oldendorf, Germany 
Cell counting chamber Neubauer improved Brand, Wertheim, Germany 
Centrifuge 5415R Eppendorf, Hamburg, Germany 
Centrifuge 5810R Eppendorf 
Centrifuge Megafuge 1.0R Heraeus, Thermo Scientific, Waltham, MA, 
United States 
Chemiluminescence imager Chemocam HR 
16 3200 
Intas Science Imaging Instruments, 
Göttingen, Germany 
Electrophoresis system, for SDS-PAGE Amersham Biosciences, GE Healthcare, 
Little Chalfont, United Kingdom 
Foil swelding machine Vacupack plus Krups, Groupe SEB, Lyon, France 
Freezer -20°C Liebherr, Bulle, Switzerland 
Freezer -80°C Heraeus, Thermo Scientific 
Heating Block Grant Instruments, Hillsborough, NJ, United 
States 
Heating Block HLC HLC Biotech, Ditabis, Pforzheim, Germany 
Ice-machine B100 Ziegra, Isernhagen, Germany 
Incubator for bacteria Memmert, Schwabach, Germany 
Incubator for bacteria Minitron Infors HT, Basel, Switzerland  
Incubator for cell culture Hera Cell 150 Heraeus, Thermo Scientific, Waltham, MA, 
United States 
Laminar flow cabinet Hera Safe Heraeus, Thermo Scientific 
Liquid nitrogen tank LS 4800 Taylor-Wharton, Theodore, AL, United 
States 
Magnetic stirrer MR Hei-Standard Heidolph, Schwabach, Germany 
Magnetic stirrer MR3001 Heidolph 
Microscope Axovert 40C Zeiss, Oberkochen, Germany 
Microscope, Axiocam MRC Scope A1  Zeiss 
Mini Centrifuge MCF-2360 LMS, Tokyo, Japan 
PCR machine for qPCR CFX96, C1000 Bio-Rad Laboratories 
PCR machine Termocycler T personal Biometra, Göttingen, Germany 
Personal computer Dell, Round Rock, TX, United States 
pH-meter WTW-720 WTW, Weilheim, Germany 
Pipet Multipette Eppendorf 
Pipet, electric Portable-XP Drummond, Broomal, PA, United States 
Pipets Eppendorf Research Series 2100 
(0.1-2.5μL; 0.5-10μL; 10-100μL; 100-
1000μL) 
Eppendorf 
Pipette, multichannel Research Plus Eppendorf 
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Power supply unit Powerpack P25T Biometra 
Refrigerator 4°C Liebherr 
Roller RM5 V-30 CAT, Staufen, Germany 
Rotator PTR 300 Grant Instruments 
Scales Acculab ALC-6100.1 Sartorius, Göttingen, Germany 
Scales LE623S Sartorius 
Scanner CanoScan 8600F Canon, Tokyo, Japan 
Sequencer, automated ABI 3100 Applied Biosystems, Life Technologies 
Shaker PROMAX 2020 Heidolph 
Sonication device Bioruptor Diagenode, Liège, Belgium 
Spectrophotometer NanoDrop ND-1000 PeqLab, Erlangen, Germany 
Thermomixer comfort Eppendorf 
Timer  Oregon Scientific, Portland, OR, United 
States 
Vacuum pump IBS Integra Biosciences, Fernwald, 
Germany 
Vortex Genie 2 Scientific Industries, Bohemia, NY, United 
States 




96-well plates for qPCR 4titude, Wotton, United Kingdom 
Bacteria culture dishes Sarstedt, Nümbrecht, Germany 
Bacteria culture vials (14 cm) Becton Dickinson 
Cell culture dishes (10 cm, 15 cm) Greiner, Frickenhausen, Germany 
Cell culture plates (6-well) Greiner 
Cell scraper (16 cm, 25 cm) Sarstedt 
Cover slips Menzel, Thermo Scientific 
Cryo tubes Cryoline Nunc, Thermo Scientific 
Filter tips (10 µL) Starlab, Hamburg, Germany 
Filter tips (20 µL, 200 µL, 1,000 µL) Sarstedt 
Glass Slides Superfrost Menzel, Thermo Scientific 
Parafilm Brand 
Pipet tips (10 µL, 20-200 µL, 1,000 µL) Greiner 
Protran nitrocellulose transfer membrane 
PVDF membrane Amersham Hybond-P 
Whatman, Dassel, Germany 
GE Healthcare, Life Sciences 
Reaction tube (0.2 mL) Sarstedt 
Reaction tube (0.5 mL, 1.5 mL, 2.0 mL) Eppendorf 
Reaction tube (15 mL, 50 mL) Greiner 
Safe-lock reaction tube (1.5 mL) Eppendorf 
Sterile filter Millipore, Merck 
Syringe Henke-Sass, Wolf, Tuttlingen, Germany 
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Syringe canula (different sizes) B.Braun, Melsungen, Germany 
Transparent sealing foil for 96-well plate 4titude 
Whatman paper Whatman 
3.3 Chemicals and reagents 
 
Acetic acid Roth, Karlsruhe, Germany 
Agar Sigma-Aldrich, St. Louis, MO, United 
States 
Albumin Fraction V (Bovine Serum Albumine, 
BSA) 
Roth 
Ammonium persulfate (APS) Roth 
Ammonium sulfate ((NH4)2SO4) Roth 
Ampicillin AppliChem, Darmstadt, Germany 
Bromophenol blue Sigma-Aldrich 
Calcium chloride dihydrate (CaCl2 x 2H2O) Roth 
Chlorodeoxyuridine (CldU) Sigma-Aldrich 
Chloroform Roth 
Complete Mini Protease Inhibitor Roche, Basel, Schweiz 
Dimethyl sulfoxide (DMSO) AppliChem 
Dithiotreitol (DTT) Sigma-Aldrich 
deoxynucleotide triphosphates (dNTPs) Bio-Budget, Krefeld, Germany 
Ethanol 99.8% Roth 
Ethanol 99.9% p.a. (EtOH) Merck 
Ethylene diamine tetraacetatic acid (EDTA) Roth 
Formaldehyde, 37% solution Roth 
Glycerol Roth 
Glycine Roth 
Glycogen blue Ambion, Life Technologies 
HEPES Roth 
Hydrogen chloride (HCl) Roth 
Immersion oil Zeiss 
Iododeoxyuridine (IdU) Sigma-Aldrich 
Isopropanol Th. Geyer, Renningen, Germany 
Lipofectamine 2000 Invitrogen, Life Technologies 
Magnesium chloride (MgCl2) for PCR Fermentas, Thermo Scientific 
Magnesium chloride hexahydrate (MgCl2 x 
6H2O) 
Roth 
Methanol >99% (MetOH) Roth 
Nailpolish  
Nonidet P-40 substitute (NP-40) Sigma Aldrich 
Nuclease free water Ambion, Life Technologies 
Peptone Roth 
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Ponceau S Roth 
Potassium chloride (KCl) Roth 
Potassium hydrogenphosphate (KH2PO4) Roth 
Prestained Protein Ladder Fermentas, Thermo Scientific 
Protein-G-Sepharose (PGS) GE Healthcare 
RNase inhibitor 
Rotiphorese Gel 30 
Fermentas, Thermo Scientific 
Roth 
Sodium acetate (NaAc) Roth 
Sodium bicarbonate (NaHCO3) Roth 
Sodium chloride (NaCl) Roth 
Sodium deoxycholate Applichem 
Sodium dodecyl sulfate (SDS) Roth 
Sodium hydrogenphosphate heptahydrate 
(Na2HPO4 x 7H2O) 
Roth 
Sodium hydroxide (NaOH) Sigma-Aldrich 
Sodium orthovanadate Sigma-Aldrich 
Sodium pyrophosphate decahydrate Apllichem 
SYBR green Invitrogen, Life Technologies 
Tetracycline Sigma-Aldrich 
Tetramethylethylenediamine (TEMED) Roth 
Trasylol Bayer, Leverkusen, Germany 
Trehalose Sigma-Aldrich 
Trisamine (Tris) Roth 
Triton X-100 Applichem 
Trizol Invitrogen, Life Technologies 
Tween 20 Applichem 
Vectashield mounting medium Vector Laboratories, Burlingame, CA, 
United States 
Yeast extract Sigma-Aldrich 
β-Mercaptoethanol Roth 
 
3.4 Buffers and solutions 
 
Cell lysis buffer 
Urea 2.5 M 
RIPA lysis buffer 100% 
for SDS PAGE, diluted with 6x laemmli 1:5 
 
CoIP buffer 
Tris, pH 7.5 50 mM 
NaCl 150 mM 
NP-40 0.20% 
Na deoxycholate 0.25% 
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Protease inhibitors  
dissolved in H2O 
 
Fiber assay blocking solution 
BSA 3.0% 
Tween 20 0.1% 
dissolved in PBS 
 
Fiber assay fixative 
MetOH 75% 
Acetic Acid 25% 
 
Fiber assay spreading buffer 
Tris, pH 7.4 200 mM 
EDTA 50 mM 
SDS 0.5% 
dissolved in H2O 
 
Laemmli buffer, 6x 




Bromophenol blue 0.02% 
dissolved in H2O 
 
Phophate buffered saline (PBS), pH 7.5 
NaCl 24.00 mM 
KCl 0.27 mM 
Na2HPO4 x 7H2O 0.81 mM 
KH2PO4 0.15 mM 
dissolved in H2O 
 
Ponceau S solution  
Ponceau S 0.5% 
Acetic acid 1.0% 
dissolved in H2O 
 
qPCR reaction buffer, 10x 
Tris, pH 8,8 750 mM 
(NH4)2SO4 200 mM 
Tween 20 0.1% 
dissolved in H2O 
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qPCR reaction mix, 25x 




MgCl2 3.0 mM 
Trehalose in 10 mM 
Tris, pH 8,5 
300.0 mM 
dNTPs 0.2 mM 
Triton X-100 0.25% 
Taq polymerase 20 U/mL 
dissolved in H2O 
 
RIPA lysis buffer, pH 7.5 
Triton X-100 1.0% 
Na desoxycholate 1.0% 
SDS 0.1% 
NaCl 150 mM 
EDTA 10 mM 
Tris, pH 7.5 20 mM 
Trasylol 50,000 KIU* 
dissolved in H2O 
*)KIU: Kallikrein Inactivator Units 
 
SDS running buffer 
Tris 25.0 mM 
Glycin 86.1 mM 
SDS 3.5 mM 
dissolved in H2O 
 
Tris buffered saline + Tween 20 (TBST), 
pH 7.6 
Tris 50 mM 
NaCl 150 mM 
Tween 20 0.1% 
dissolved in H2O 
 
Western blot blocking solution 
BSA 5% 
dissolved in TBST 
 
Western blot buffer, pH 8.3 
Tris 25 mM 
Glycin 192 mM 
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MetOH 20% 
dissolved in H2O 
3.5 Chemotherapeutics 
Name Systematic name Company 
Gemcitabine 2',2'-difluorodeoxycytidine (dFdC) Eli Lilly, Indianapolis, IN, 
United States 
3.6 Inhibitors 
Name Commercial name Target Company 
ATM Inh KU55933 ATM Selleckchem 
Caspase Inh  Z-VAD-FMK  Caspases  Enzo Life Sciences 
MK2 Inh  MK2 III  MK2 Calbiochem, Merck  
MKP1 Inh BCI.HCl MKP1 Sigma-Aldrich  
3.7 Enzymes and buffers 
Reagent Company 
Buffer for M-MuLV RT, 10x New England Biolabs, Ipswich, MA, United States 
Buffer for Taq with KCl, 10x Fermentas, Thermo Scientific 
M-MuLV Reverse transcriptase (RT) New England Biolabs 




BigDye Terminator v3.1 Cycle Sequencing kit Invitrogen, Life Technologies 
Immobilon Western HRP Substrate Peroxide 
Solution  
Millipore, Merck 
Invisorb Spion Plasmid Mini Kit Two Invitec, Stratec, Berlin, Germany 
PureYield Plasmid Midiprep System Promega 
SuperSignal West Femto Maximum Sensitivity 
Substrate 
Thermo Scientific 
3.9 small interfering RNAs 
Name (identifies target) Sequence 
Negative Control No. 2 undisclosed 
MKP1 sense: 5’-CCACCACCGUGUUCAACUUtt-3’ 
antisense: 5’-AAGUUGAACACGGUGGUGGtg-3’ 
 
All siRNAs are Silencer Select from Ambion, Life Technologies.  
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3.10 Primers 
Name Sequence Application 
BGH reverse 5’-TAGAAGGCACAGTCGAGG-3’ sequencing 
CMV forward 5’-CGCAAATGGGCGGTAGGCGTG-3’ sequencing 
XL39 reverse  5’ATTAGGACAAGGCTGGTGGG-3’ sequencing 
VP1.5 forward 5’-GGACTTTCCAAAATGTCG-3’ sequencing 
anchored oligo-dT dT23VN RT-PCR 
random nonamer 5’-NNNNNNNNN-3’ RT-PCR 
Cdc7 forward 5’-AGATTGAGGACAAAATTGGAGAA-3’ 
qPCR 









Name Source Description 
pcDNA3.1 Invitrogen, Life 
Technologies 
Expression vector for the 
exogenous expression of proteins 
under the control of a CMV 
promoter in eukaryotic cells; 
ampicillin resistance. See Fig. 7.6 
for vector map.  
pcDNA3.1-Mcl-1-V5-His-
TOPO 
Addgene Plasmid 25375, 
gift from Roger Davis 
pcDNA3 vector with open reading 
frame coding for human Mcl-1 
inserted in the MCS.  
pCMV6-Myc-DDK-DUSP1 Origene, RC205220, 
NM_004417 
pCMV6-Entry vector with open 
reading frame for human DUSP1 
(alias MKP1) inserted in MCS. See 
Fig. 7.6 for vector map. 
pCMV6-Flag-Mcl-1 Addgene Plasmid 25392, 
gift from Roger Davis 
pcDNA3 vector with open reading 
frame coding for human Mcl-1 
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3.12 Antibodies 
Primary antibodies (Dilutions are given for immunoblotting unless mentioned) 
 
Target Clone Source 
organism 
Dilution Company 
ATR N-19 goat 1:300 Santa Cruz Biotechnology, Santa 
Cruz, CA, United States 
ATRpT1989  rabbit 1:300 Kerafast 
BrdU/CldU BU1/75 
(ICR1) 




BrdU/IdU B44 mouse 1:500 for 
immunostaining 
Becton Dickinson 
Cdc7 DCS341 mouse 1:1,000 Abcam 
Cdc7 SPM171 mouse 1:1,000 Santa Cruz Biotechnology, Santa 
Cruz, CA, United States 
Chk1 2G1D5 mouse 1:1,000 Cell Signaling Technology 
Chk1pS317  rabbit 1:1,000 Cell Signaling Technology 
Chk2pT68 C13C1 rabbit 1:1,000 Cell Signaling Technology 
Claspin  rabbit 1:1,000 Cell Signaling Technology 
H2AX pS319  rabbit 1:1,000 Cell Signaling Technology 
Hsc70 B-6 mouse 1:10,000 Santa Cruz Biotechnology, Santa 
Cruz, CA, United States 
Hsp27 pS82  rabbit 1:1000 Cell Signaling Technology 
IgG  rabbit 3 µG for pulldown Abcam 
JNK pT183/Y185  rabbit 1:1,000 Cell Signaling Technology 
Mcl-1  rabbit 1:1,000 Cell Signaling Technology 
MCM2pS53 EP4120 rabbit 1:10,000 Abcam 
MKP1  rabbit 1:1,000 Millipore 
Myc-tag 4A6 mouse 1:1,000 Millipore 
p38pT180/Y182  rabbit 1:1,000 Cell Signaling Technology 
p53 DO-1 mouse 1:1,000 Santa Cruz Biotechnology, Santa 
Cruz, CA, United States 
β-Actin AC-15 mouse 1:20,000 Abcam 
β-Galactosidase  mouse 3 µG for pulldown Promega 
 
 
MATERIALS                                                                                                                            31 
 
3.13 Secondary antibodies 
Antibody Cat. Number Company 
Alexa-Fluor-488 goat anti mouse A-11017 Invitrogen, Life Technologies 
Alexa-Fluor-555 goat anti rat A-21434 Invitrogen, Life Technologies 
HRP-coupled AffiniPure F(ab')2 
fragment, anti mouse IgG (H+L)  
711-036-152  Jackson Immunoresearch 
HRP-coupled AffiniPure F(ab')2 
fragment, anti rabbit IgG (H+L)  
715-036-150  Jackson, Immunoresearch  
3.14 Human cell lines 
Cell line  Type 
Jurkats Acute T-cell leukemia 
MIA PaCa-2 Pancreatic adenocarcinoma 
U2OS Osteosarcoma 
 
3.15 Media and reagents for eukaryotic cell culture 
Reagent Company 
Ciprofloxacin Bayer 
Dulbecco’s Modified Eagle Medium (DMEM), powder Gibco, Life Technologies 
Fetal Calf Serum (FCS) Gibco, Life Technologies 
L-Glutamine Gibco, Life Technologies 
PBS (tablets) Gibco, Life Technologies 
Penicillin/Streptomycin Gibco, Life Technologies 
RPMI Medium Gibco, Life Technologies 
Tetracyclin Gibco, Life Technologies 
Trypsin/EDTA Gibco, Life Technologies 
 
DMEM  
DMEM, powder 10.0 g 
NaHCO3 3.7 g 
HEPES 5.96 g 
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3.16 Bacteria strain 
 
Strain Description Company 
DH10B  Chemically competent E.coli Self made 
 
 








YT agar 15% 





CFX Manager Software for 
qPCR cycler  
Bio-Rad 
Excel Microsoft, Redmond, WA, United States 
Graph Pad Prism GraphPad Software, Inc. 
INTAS labID  Intas Science Imaging Instruments 
Nanodrop Software Peqlab 
Fiji General Public License 
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4. Methods 
4.1 Cell biology 
4.1.1 Culturing of human cells 
All cell culture work was performed under laminar flow hoods and sterile conditions were 
maintained. Hoods were always cleaned with 70% ethanol prior to usage and only 
autoclaved pipettes and tips were used. The reagents used for cell culture were prepared 
and opened under the hood. Adherent U2OS cells were grown at 37 °C with 5% CO2, in 
coated petri dishes using pre-warmed DMEM full medium (composition given in Table 4.1). 
For sub-culture, cells were washed once with 1X PBS and trypsinized for 5 to 7 min using 
0.1% trypsin/EDTA. This led to the detachment of cells from the plate after which an equal 
volume of DMEM was added to inactivate trypsin. Afterwards, these floating cells were put in 
a falcon and centrifuged at 1000 rpm for 5 min, supernatant was discarded and cells were re-
suspended in full culture medium. Depending on the requirement, cells were reseeded at 
dilutions of 1:5 to 1:10, two to three times per week. For experiments, cells were counted 
using a Neubar chamber and re-seeded at an appropriate density in either 6-well plates (for 
all immunoblot and IP experiments) or 50 mL flasks (for all the DNA fiber assays).  
 
Table 4.1 Culture Medium. 
Cell line Medium composition 
U2OS DMEM 
 10%FCS 
 50 U/mL penicillin 
 50 U/mL streptomycin 
 200 µM L-glutamine 
 10 µg/ml ciprofloxacin 
 
4.1.2 Freezing of cells 
Cells were frozen and stored for later usage. For this purpose, low-passage (passage 
number 3 or 4) cells were grown in a 15 cm dish to full confluence and later trypsinized in the 
same manner as described above (4.1.1). All the cells were centrifuged at 1000 rpm for 5 
min, supernatant was removed and cells were re-suspended in pre-cooled freezing medium 
(FCS with 10% DMSO). The cell suspension was transferred to cryo vials, which was 
immediately kept in a pre-cooled isopropanol box at -80 °C to allow slow cooling, and 24 h 
later shifted to liquid nitrogen tanks.  
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4.1.3 Thawing of frozen cells 
Cells frozen as described above were thawed when required. To this end, aliquots were held 
under lukewarm running water (37 °C) for around a minute, and rapidly transferred into a 50 
mL flacon containing pre-warmed full medium. The cells were centrifuged for 5 min at 1000 
rpm, re-suspended in fresh medium and seeded in a 5 cm petri dish.  
4.1.4 Inhibitor and chemotherapeutic treatment 
Chemotherapeutics and inhibitors were ordered in powder form and later dissolved (under 
the cell culture hood) in an appropriate solvent at the desired stock concentration (Table 4.2). 
For experiments, these drugs were used at the concentrations given in Table 4.2, by 
dissolving the required volumes from the stock in medium. An equivalent volume of the 
solvent was added in the control. In cases when volumes were lower than 0.4 µL, a master 
mix of the drug/solvent was prepared in medium and used. 
Table 4.2 Concentrations of inhibitors and chemotherapeutics used in cell culture. 
 
4.1.5 Transfection of human cells 
4.1.5.1 Transient transfection with siRNAs 
We employed RNA interference strategy to silence our gene of interest. This was achieved 
by transient reverse transfection of U2OS cells with small interfering RNA’s (siRNA) using a 
lipid based transfection agent, lipofectamine 2000. For carrying out this procedure, 
lipofectamine and siRNA were dissolved separately in DMEM only medium (without FCS, 
Glu and antibiotics) as outlined below (Table 4.3), and incubated at room temperature (RT) 
for 5 min. 
 
 
Chemical Solvent Stock Final 
concentration 
BCI (MKP1 Inh) DMSO 10 mM 1 / 3 / 5 µM 
Gemcitabine H2O 64 mM 400 / 500 nM 
KU55933 (ATM Inh)  DMSO 10 mM 10 µM 
MG132 (Proteasome Inh) DMSO 10 mM 10 / 20 µM 
MK2III (MK2 Inh) DMSO 10 mM 10 µM 
Z-VAD-FMK (Caspase inh) DMSO 10 mM 25 / 40 µM 
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Table 4.3 Concentration and volume of siRNA and lipofectamine used for transient 
transfections. 
MKP1 siRNA DMEM only Lipofectamine 2000 DMEM only 
0.4 µL for 10 nM siRNA 200 µL 4 µL 200 µL 
0.6 µL for 15 nM siRNA 200 µL 6 µL 200 µL 
 
Later, they were combined and incubated for another 20 to 40 min at RT. In the meantime, a 
~ 80% confluent U2OS plate was trypsinized; cells were collected in a falcon and counted. In 
one well of a 6-well plate, around 280,000 cells were seeded in 1.6 mL DMEM full medium 
(well-surface: 3.6 cm2); and 400 µL of the prepared lipofectamine-siRNA mix was added 
drop-wise. Media was changed after 24 h, and cells were grown in full medium without 
siRNA for an additional 24 h. For the experiments which involved the use of certain inhibitors, 
details have been mentioned in their figure legends. 
4.1.5.2 Transient transfection with expression vectors 
To over-express a protein, we used expression vectors encoding the complementary DNA 
(cDNA) sequence of the desired gene and did forward transfection with lipofectamine 2000. 
For this, ~ 320,000 U2OS cells were seeded per well in a 6-well plate and incubated 
overnight at 37 °C with 5% CO2. Next day, the desired amount of plasmid DNA and 
lipofectamine 2000 were separately dissolved in DMEM only medium (Table 4.4) for 5 min, 
then mixed, incubated for 20 to 40 min at RT. The media from the cells was sucked off and 
the prepared 400 µL DNA-lipofectamine mix was added to the cells drop-wise. Media was 
changed after 4 h and experiments were performed (Co-IP) 24 h after transfection. The 
details of Co-IP are explained in 4.2.6. 
Table 4.4 Concentration and volume of siRNA and lipofectamine used for transient 
transfections. 
Plasmid DMEM only Lipofectamine 2000 DMEM only 
375 nG DNA 200 µL 1 µL 200 µL 
0.8 µG DNA 200 µL 2 µL 200 µL 
1.6 µG DNA 200 µL 4 µL 200 µL 
2.4 µG DNA 200 µL 6 µL 200 µL 
 
In the experiments where siRNA and plasmid transfections were combined, cells were first 
reverse transfected with siRNA and 24 h later forward transfected with the plasmid DNA of 
interest. After 4 h of plasmid transfection, media was changed. Cells were grown in full 
medium for an additional 24 h and later harvested for SDS-PAGE analysis as described 
below.  
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4.2 Biochemistry techniques  
4.2.1 Preparation of cell lysates for protein separation by SDS-PAGE 
To make whole cell lysates, cells from 6-well plates were scrapped off in medium by gentle 
strokes using a 25 cm rubber cell scrapper and transferred to 1.5 mL reaction tubes, on ice. 
This was followed by centrifugation at 4600 rpm, 4 °C for 10 min.  The resulting supernatant 
was sucked off using a vacuum pump and pellet was washed once with PBS. This was 
subjected to a second round of centrifugation like before, and the resulting pellet was lysed 
using 100 µL RIPA or Co-IP lysis buffer (with protease inhibitors) depending on the 
experiment. Further, lysates were shaken at 1000 rpm for 15 min in the cold room to shear 
DNA; which was later spun down at 13000 rpm, 4 °C for 10 min. The supernatant containing 
all the proteins was utilized for protein estimation using the bicinchoninic acid (BCA) assay. 
For loading onto gels, appropriate volume of protein lysate was taken into a new reaction 
tube and a desired volume of 6x laemmli buffer was added such that the final concentration 
of laemmli was 1x. Lysates were shaken at 95 °C for 5 min to denature the proteins, and 
quickly spun down using a mini table top centrifuge.  
4.2.2 Bicinchoninic acid (BCA) assay for protein estimation 
Protein estimation was done using Pierce BCA Protein Assay Kit. This method takes 
advantage of a protein’s ability to reduce copper from its Cu+2 to Cu+1 state in an alkaline 
environment. In the first step, peptides react with Cu+2 ions and reduce it to Cu+1 under the 
influence of an alkaline medium provided by sodium potassium tartrate. This yields a light 
blue color. To increase the sensitivity of this reaction for an easier detection, a second step 
converts the pale blue color to dark purple where two molecules bicinchoninic acid (BCA) 
react with one Cu+1 forming a water soluble BCA-copper complex which absorbs light 
strongly at 562 nm. To perform the BCA test, we followed the protocol as given in the user 
manual. For one reaction cocktail, reagent A and B were mixed in a ratio of 98:2 to which 5 
µL protein lysate was added and incubated at 37 °C for 30 min. 2 µL of the resultant dark 
purple complex was measured at 562 nm using a nanodrop spectrophotometer. As a control, 
5 µL lysis buffer was used instead of the protein. A BSA standard curve was also prepared in 
a similar way, and the unknown protein concentration was calculated using this reference.  
4.2.3 Separating proteins using SDS-PAGE 
Electrophoretic mobility of proteins can be exploited to separate them on a polyacrylamide 
gel according to their molecular weight. This is called PAGE (Polyacrylamide Gel 
Electrophoresis). However, in 1970, U. K. Laemmli refined this technique using denaturing 
conditions provided by SDS (Sodium Do-decyl Sulphate) (Laemmli 1970). Here, proteins 
were boiled in laemelli buffer containing SDS and a reducing agent (DTT or β-
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mercaptoethanol). While reducing agents were used to break the disulfide bonds; anionic 
SDS binds to proteins in amounts proportional to its molecular mass and imparts an overall 
negative charge. This denaturation ensured the separation of proteins according to their 
molecular mass. During electrophoresis, all proteins moved towards anode due to their 
negative charges but their migration rate was different depending on their mass. Heavier 
proteins traveled much slower as compared to the lighter proteins which moved faster 
through the pores of acrylamide. The discontinuous acrylamide gel was composed of two 
layers – an upper 5% stacking gel with a pH of 6.8; and a lower resolving gel of pH 8.8 with a 
higher percentage of acrylamide (12%). The lower percentage stacking gel having big pores, 
allowed all the proteins to travel at almost the same rate and ‘stack’ together as a single 
band before entering the lower gel, where the proteins separation took place. Table 4.5 
summarizes the composition of the gels. 10 µG of protein lysate was loaded on the gel after 
BCA estimation along with a pre-stained protein ladder to monitor protein separation and to 
estimate their size. The gels were run in SDS running buffer at a constant voltage of 100 V 
for 3 h. 
Table 4.5 Composition for one gel. 
Components Stacking gel 5% 
(mL) 
Resolving gel 12% 
(mL) 
ddH2O 8.4 13.2 
Acrylamide/Bisacrylamide 2 16 
Tris pH 6.8 1.52 - 
Tris pH 8.8 - 10 
10% SDS 0.12 0.4 
10% APS 0.12 0.4 
TEMED 0.012 0.019 
 
4.2.4 Immunoblotting 
Immunoblotting or Western blotting is an analytical technique developed in 1979 by Towbin 
and his co-workers for the detection of proteins (including post translational modifications 
and protein-protein interactions) after separating them on a SDS-PAGE (Towbin, Staehelin et 
al. 1979). By applying current, proteins are transferred from the gel to a nitrocellulose 
membrane. Once on the membrane, proteins are detected using a specific primary antibody 
raised against a particular epitope of the protein. Subsequently, a secondary antibody 
coupled to a horseradish peroxidase enzyme is added to the membrane which is capable of 
binding to the constant region of first antibody thus making it possible for a species-specific 
recognition. The enzyme oxidizes its substrate, luminol, in the presence of H2O2 to produce 
light which can be recorded by a camera. Since the light emitted is proportional to the 
amount of enzyme bound, a rough estimation of the amount of protein can be made. 
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In our lab we used the method of wet western blotting to detect proteins. In this technique, a 
stack of whattmann filter paper, gel and nitrocellulose membrane was assembled. The gel 
was kept facing the anode side (plus end) to allow for transfer onto the membrane. This 
sandwich was kept in a running chamber with pre-cooled transfer buffer, and run at a 
constant voltage of 100 V for 2 h at 4°C. Once transfer was done, membrane was stained 
with Ponceau-S and a picture was taken. This allowed us to cut the membrane into small 
pieces to stain for different proteins. Ponceau-S stain was washed off with transfer buffer. 
Later, membrane was blocked for 1 h, at RT with 5% milk prepared in TBS-T, washed twice 
with TBST and incubated overnight at 4°C with different primary antibodies prepared in 5 % 
BSA (made in TBS-T). Next day, the membranes were washed three times with TBST and 
blocked with milk for 15 min to avoid unspecific binding by the secondary antibody. This was 
followed by the addition of secondary antibody for 1-2 h, at RT (donkey anti mouse or donkey 
anti rabbit; prepared in milk). Thereupon, membranes were blocked with milk for 15 min and 
washed thrice with TBST.  
Detection was made possible by using the Immobilon Western Chemiluminescent HRP 
Substrate (Millipore) or SuperSignal West Femto Maximum Sensitivity Substrate (Thermo 
Scinetific). For every 4 cm * 5 cm membrane, 500 µL of HRP substrate was mixed with 500 
µL of peroxide solution, added to the membrane and incubated for 2 min. Luminescence was 
detected on INTAS Image using a Chemocam HR 16 3200 imager.  
4.2.5 Quantitative Reverse Transcription- Polymerase Chain Reaction (qRT-
PCR) 
To monitor gene expression, mRNA levels were quantified using quantitative Reverse 
Transcription - Polymerase Chain Reaction (qRT- PCR). This required the isolation of total 
RNA from the cells, followed by its conversion into complementary DNA (cDNA) with the 
enzyme Reverse Transcriptase, and finally amplification of the cDNA using PCR. These 
steps are described in detail below. 
4.2.5.1 Total RNA isolation 
Total RNA was extracted from human cells using the readily available guanidium-
isothiocyanate-phenol solution, TRIzol, under the fume hood. For each well of a 6-well plate, 
cells were washed with 1 mL PBS and later lysed using 1 mL TRIzol for 5 min at RT. Cells 
were carefully re-suspended for homogenization and transferred to a 2 mL eppendorf tube. 
To isolate RNA from the proteins, 200 µL of chloroform (per mL of TRIzol) was added and 
shaken vigorously for 15 sec. This was centrifuged at 13,200 rpm, 4 °C for 45 to 60 min. The 
resulting upper aqueous phase containing RNA was carefully separated without touching the 
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interphase, and transferred into a clean 1.5 mL tube. RNA was precipitated from this phase 
using 500 µL isopropanol per 1 mL TRIzol. Samples were mixed thoroughly and incubated at 
RT for 10 min after which they were centrifuged at 13,200 rpm, 4 °C for 60 min. Supernatant 
was discarded and RNA pellet was washed twice with 1 mL 70% Ethanol and spun down at 
9000 rpm, 4 °C for 20 min. RNA was air dried for 15 min under fume and dissolved in 15 µL 
nuclease free water. Following this, they were incubated at 55 °C with mild vortexing. RNA 
concentration was measured using the nanodrop and stored at -80 °C. 
4.2.5.2 Synthesis of cDNA (RT) 
Using viral M-MuLV reverse transcriptase, mix of anchored oligo-dT23VN primers and random 
nonamers; the isolated RNA was converted to complementary DNA. The reaction cocktail 
was prepared in clean PCR tubes as follows: 1 µg of RNA was combined with 2 µL of mixed 
primer, 0.5 µL dNTP mix and volume was made up to 16 µL with autoclaved water. This was 
heated at 70 °C for 5 min to remove RNA secondary structures; and put on ice after a brief 
spin in a table top micro centrifuge. Here, each sample was prepared in a duplicate. In one 
set of RNA samples, RT master mix was added (4 µL mix per sample), and in the other set, 
the samples were mixed with a master mix which was prepared without the RT enzyme (4 µL 
mix per sample). Composition of master mix is given below (Table 4.6): 
Table 4.6 Components of RT reaction master mix. 
Components Volume (µL) Master mix 
(e.g. 8 samples) 
RT 10X Reaction Buffer 2 17 
RNase inhibitor (10 U) 0.25 2.125 
M-MuLV Reverse Transcriptase (25 U) 
Or autoclaved water 
0.125 1.062 
Autoclaved water 1.625 13.812 
  
All this work was performed in RNase-free surrounding on ice. After the samples were 
prepared, they were incubated at 42 °C for 1 h for the reverse transcription to take place. 
Subsequently the enzyme was inactivated by heating the samples to 95 °C for 5 min. Each 
sample was then diluted by the addition of 30 µL nuclease free water. DNA concentration 
was measured using the nanodrop and stored at -20 °C.  
4.2.5.3 Amplification of cDNA using quantitative real time PCR  
cDNA generated in the previous step was amplified and detected in real time as the reaction 
progressed. This was achieved by the use of a fluorescent dye - SyBr Green in our 
experiments, which intercalated into the DNA and was used to measure the amount of DNA 
generated after every replication cycle. To calculate relative abundance of the gene of 
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interest, a reference gene was chosen whose expression levels remained constant under 
various conditions (36B4 in our experiment). Later, all the values obtained from the gene of 
interest were normalized to this reference gene. To specifically amplify cDNA arising from the 
mRNA of our interest, sequence-specific primers were designed. Since the sensitivity of PCR 
is best when the product size is between 150-300 bp, forward and reverse primers were 
generated spanning the exon-junctions in such a way that only a small fragment of the cDNA 
was amplified. For one reaction mix, the components were mixed as given in the table below. 
To keep things simple, a master mix of all the components (without the cDNA) was prepared 
and 24 µL of this master mix was added to 1 µL of cDNA. cDNA resulting from RT reactions 
without reverse transcriptase and qPCR samples without cDNA template served as controls. 
All samples were analyzed in triplicates. The qPCR reaction mix and the qPCR cycler 
program are detailed below in Table 4.7 and 4.8. 
Table 4.7 Components of qPCR mix for one sample. 
Components Volume (µL) 
25X qPCR reaction mix 14 
Forward primer (10 pmol/µL) 0.75 
Reverse primer (10 pmol/µL) 0.75 
cDNA 1 
Nuclease free water 8.5 
 
Table 4.8 Cycler program for qPCR. 
Temperature Time  
95°C 2 min 
95°C 15 sec  
40X 60°C 1 min - read 
 
The fluorescence of each sample was measured after every cycle at the end of elongation 
(“read”). Purity of the qPCR product was controlled with a melting curve that should yield a 
single melting point for a specific product. The resulting Ct values (amplification cycle at 
which the fluorescence reaches the determined threshold) were used for the calculation of 
the relative amount of template using the Δ ΔCt method, assuming 100% amplification 
efficiency (i.e. a product doubling with each cycle): relative mRNA expression = 2 (ΔCt ref. gene 
treated/target gene treated) – (ΔCt ref. gene untreated/target gene untreated) 
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4.2.6 Co-immunoprecipitation 
To identify protein-protein interactions, the technique of co-immunoprecipitation (Co-IP) was 
used. In this method, target proteins are first captured using specific antibodies, which is later 
analyzed for the interacting partner. Here, cell lysates are first incubated with the antibody 
against the protein of interest, which helps to precipitate it. In this manner, the proteins bound 
to the target proteins are also precipitated, in a complex. After this step, the complex is made 
to bind with Protein A or Protein G coupled sepharose beads. Protein A and Protein G are 
bacterial proteins which can bind to the constant region of antibodies, thus facilitating the pull 
down of the antibody-target protein complex. The proteins which do not bind to the beads are 
washed away after multiple steps of washing, leaving a purified protein complex. These 
precipitated proteins are later identified with a SDS-PAGE followed by an immunoblot (see 
4.2.3 and 4.2.4). Co-IP can be done in a native system or in an over-expression system 
using plasmids to over-express the proteins whose interaction needs to be monitored. To 
look for a possible interaction between MKP1 and Mcl-1, over-expressing plasmids of both 
proteins were used and a Co-IP was performed. On the day before the experiment, U2OS 
cells were seeded at a density of 280,000 cells per well of a 6-well plate. Next day, cells were 
transiently transfected for 24 h with pcDNA3; Flag tagged hMcl-1 (Morel, Carlson et al. 2009) 
and Myc-DDK tagged-hDUSP1 using lipofectamine, in the manner as described in Table 4.9. 
The hMcl-1 and hDUSP1 plasmids were on a CMV backbone.  
Table 4.9 Amount of plasmids used for transient transfections in Co-IP. 
Plasmid µG 
pcDNA3 2.4 
hMcl-1 + pcDNA3 0.8 + 1.2 
hDUSP1 + pcDNA3 1.6 + 0.8 
hMcl-1 + hDUSP1 0.8 + 1.6 
 
After transfection, cells were washed once with 5 mL ice cold PBS and harvested using 500 
µL Co-IP buffer on ice. Cell lysates from three wells of the same condition was pooled 
together, and transferred to a 2 mL reaction tube. The cell lysate was homogenized by 
pushing it through a 26 G insulin syringe for 5 times. This was followed by sonification of the 
cell lysate to destroy the DNA. Later, samples were centrifuged at 13,000 rpm, 4 °C for 15 
min, to get rid of the cell debris. The resulting supernatant was transferred to a new reaction 
tube and incubated with 75 µL of pre-washed protein G sepharose (PGS) for 1 h on a rotator 
at 4 °C. This is called the pre-clearing step, which is essential to remove proteins that bind 
unspecifically to the beads. Pre-washing of PGS is done before by suspending the beads 
three times in Co-IP buffer with short spins in between for 2 min at 3000 rpm, 4 °C. After 
incubating the lysate with beads, samples were centrifuged for 4 min at 3000 rpm, 4 °C, and 
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supernatant was transferred into a new tube. Around 20-50 µL of lysate from each sample 
was taken out and mixed with 15 µL of 6x laemelli, for the input control. Now, each of these 
samples was divided into two parts. For one of the experiments where MKP1 was pulled 
down, one part of each sample was incubated with mouse anti β-galactosidase and the other 
part was incubated with mouse anti Myc-tag. For the second experiment where Mcl-1 was 
pulled down, one part of each sample was incubated with rabbit anti IgG and to the other part 
rabbit anti Mcl-1 was added. The mouse anti β-galactosidase and rabbit anti IgG worked as 
negative controls for the pull down. Antibodies were used at a concentration of 3 µG. Then, 
20 µL 50% PGS was added to each sample and incubated at 4 °C for 1 h on a rotator. This 
step assisted the coupling of the beads to the antibody-protein complex. This complex was 
centrifuged for 2 min at 3,000 rpm, 4 °C, and supernatant was discarded. The beads were 
then washed with 800 µL Co-IP lysis buffer for five times, with spins in between for 2 min at 
3000 rpm. At the last washing step, the supernatant was carefully removed using a syringe. 
The pellet was re-suspended in 25 µL 3x laemmli buffer and boiled for 5 min at 95 °C, 
together with input controls. Samples were centrifuged to spin down the beads, and 
supernatant was used for loading on SDS PAGE Samples were analyzed by immunoblotting 
followed by chemiluminiscence detection. For the experiment where MKP1 was pulled down, 
rabbit anti Mcl-1 antibody was used for detection after blotting and in the experiment where 
Mcl-1 was pulled down, mouse-anti Myc antibody was used. 
4.3 Molecular biology 
4.3.1 Heat-shock transformation of chemical competent bacteria 
Transformation is the process where chemically competent bacterial cells take up any 
exogenous material, like DNA. This method is used for rapid amplification of plasmid DNA. 
Chemical competent E.coli cells, DH10B were used for this purpose. In this procedure, 1 µL 
of plasmid DNA was incubated with 50 µL of these competent cells. This was incubated for 
30 min on ice and later for 10 min at 37°C. This heat-shock allows the uptake of DNA. After 
this, cells are again kept on ice for an additional 10 min and then 200 µL 2YT media was 
added. These bacteria were incubated for 30-60 min at 37 °C with shaking at 300 rpm. This 
allowed the bacteria to grow, and this culture was then used for plating on agar plates with 
appropriate antibiotics (Kanamycin 25 µG/mL, Ampicillin 100 µG/mL). pCMV-Flag-hMcl-1 
was a gift from Roger Davis (Addgene plasmid # 25392), pBabe-Flag hMcl-1 was a gift from 
Roger Davis (Addgene plasmid # 25371), DUSP1 (Myc-DDK-tagged)-Human dual specificity 
phosphatase 1 (DUSP1) was ordered from Origene (plasmid RC205220, NM_004417).   
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4.3.2 Plasmid DNA isolation 
Plasmid DNA was isolated from a transformed bacterial culture which was grown the 
previous night in 2YT medium with appropriate antibiotics. To isolate and purify the plasmid 
DNA in large volumes, the PureYield™ Plasmid Midiprep System (Promega) was used 
according to the manufacturer’s instructions. For a smaller volume the Invisorb Spin Plasmid 
Mini Kit Two (Invitec) was used according to the manual.  
4.3.3 Measurement of nucleic acid concentration 
DNA concentration was measured using a spectrophotometer, NanoDrop 
Spectrophotometer, ND-1000 (PeqLab). 2 µL of sample was used to measure the absorption 
co-efficient at 260nM. This was later used to calculate the corresponding DNA in the sample. 
Water was used as a blank. For measuring RNA, same procedure was followed. 
4.3.4 Sequencing of DNA 
The plasmid DNA obtained from midi prep, or from outside has to be sequenced before 
proceeding with the experiment. This was done using the BigDye® Terminator v3.1 Cycle 
Sequencing Kit. This is based on the method that was originally developed by Sanger and 
colleagues (Sanger, Nicklen et al. 1977). This method utilizes fluorescent dideoxynucleotides 
(ddNTPs) which lack the 3’-OH group. Thus, when such a ddNTP is incorporated, then the 
elongating chain terminates. This chain termination leads to the formation of PCR products of 
varied lengths, which are later separated in a gel matrix. The fluorescence from the ddNTPs 
of each fragment size is then used in sequence analysis. For the sequencing PCR, 100 ng of 
plasmid DNA was mixed with 30 pmol of the appropriate primers and 2x sequencing mix. 
The sequencing mix was composed of polymerase, dNTPs and fluorescently-labeled 
ddNTPs. The program used for sequencing PCR is given in Table 4.10  
Table 4.10 Cycler program for sequencing PCR. 
Temperature Time  
96°C 2 min 
96°C 10 sec 
55°C 15 sec 20x 
60°C 4 min  
12°C pause 
 
The PCR product was purified by ethanol precipitation and resuspended in Hi-Di Formamide 
for sequencing using an ABI 3100 Automated Capillary Sequencer.  
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4.4 DNA fiber assay 
Replication dynamics was monitored using the DNA fiber assay, based on the protocol 
published by Jackson and Pombo (Jackson and Pombo 1998). In this assay, cells are first 
pulse-labeled with 5-Chloro-2′-deoxyuridine (CldU) and later with 5-Iodo-2′-deoxyuridine 
(IdU). Since CldU and IdU are nucleoside analogs, they get incorporated into the replicating 
DNA strand and mark progressing replication forks. This is followed by cell harvest and lysis. 
DNA is spread on a glass slide and fixed with methanol/acetic acid. Subsequently, DNA is 
denatured using hydrochloric acid treatment to expose the single strands; blocked and 
stained with specific primary and fluorescent-dye-coupled secondary antibodies. Such an 
immunofluorescence based method allows the detection of labeled DNA tracks using a 
fluorescence microscope. The resulting fork structures are as shown in Fig. 4.1. Using this 
technique replication fork speed, frequency of origin firing and replication termination can be 
calculated. Replication fork speed is calculated using the uni-directional structures. If a 
treatment is applied before the first pulse label, the total track length of CldU and IdU is taken 
for subsequent calculations. When cells are pretreated with the appropriate drugs, it is also 
possible to analyze how origin firing is affected. To assess origin firing, the ongoing, 
bidirectional forks (1st label origins) are counted, and later presented as a percentage of all 
red label structures. Since these are the origins which fired when the first label was applied, if 
the drug treatment had changed the rate of origin firing, it should be easily detectable by 
such quantification. 
For performing the DNA fiber assay, a day before the experiment, 5 x 105 U2OS cells were 
grown exponentially in 25 mL flasks with 5 mL medium for 16-20 h. In addition, 25 µM of 
CldU and 250 µM IdU was prepared in medium by appropriate dilutions from the stock 
solutions. The diluted labels and a flask of fresh medium were left to equilibrate overnight at 
37 °C in the incubator. On the day of experiment, inhibitors and chemicals were diluted in the 
different media (CldU medium, IdU medium or fresh medium alone), depending on the 
experiment. For pre-treating cells, inhibitors were first diluted in the fresh medium prepared 
the previous night and left to incubate for approximately 15 min in the incubator. 
Subsequently, cells were taken out of the incubator, and its medium was aspirated. This was 
followed by the addition of the inhibitor containing medium, and cells were left to incubate for 
1 h at 37 °C in the incubator. During this time, inhibitors were added to the CldU and IdU 
containing media, and left to equilibrate at 37 °C. After 1 h, the medium was aspirated and 
the CldU-inhibitor containing medium was added. After 30 min of CldU label, this medium 
was replaced with the IdU-inhibitor medium for an additional 30 min. The IdU concentration 
used was ten times higher than CldU to ensure that CldU is not incorporated any more 
during the second label. When the experiment involved the use of gemcitabine, it was added 
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only to the second label. After IdU treatment, cells were kept immediately on ice to stop 
further replication. Medium was aspirated, and cells were washed twice with ice cold PBS. 
Subsequently, cells were harvested in 2 mL PBS with gentle strokes using a 16 mL scrapper. 
Cells were collected in a 2 mL tube, and centrifuged at 4,400 rpm at 4 °C for 7 min.  The 
resulting supernatant was removed using a needle and pellet was re-suspended in 100 µL of 
PBS. Cells were counted and samples were diluted to obtain a final density of 5 x 105 cells 
per mL. 2 µL drop of each sample was placed at the top end of superfrost, glass slide. This 
was allowed to stand at RT for approximately 3-4 min, after which 7 µL of spreading buffer 
was added and incubated for another 2 min. After this the slide was tilted to form a nose, and 
the drop was made to run down the slide slowly at a speed of around 3 cm/min. In this way, 
the DNA is spread on the slide, which is left to air-dry for 30 min and later fixed in the fiber 
assay fixative for 10 min. These slides can be stored up till one month at 4 °C.  
 
Figure 4.1 Representative images of the various structures analyzed in DNA fiber assay 
CldU was the first pulse label given to the cells, which was detected by a specific rat anti BrdU primary 
antibody and red fluorescent secondary antibody. Similarly, IdU was the second pulse label given, 
which was detected by mouse anti BrdU primary antibody and subsequently by a green fluorescent 
secondary antibody. Analysis was done using Fiji. Ongoing, uni-directional forks were measured for 
their lengths in pixels which was later used for calculating the rate by conversion to µm and kilo bases 
(1 µm = 2.59 kb). Origin firing was quantified by counting the 1st label origins and representing it as a 
percentage of all red-labeled fibers (1-4). (Based on Köpper et al., PNAS 2013 and Petermann et al., 
PNAS 2010). 
For immunostaining, wet chamber was used to avoid the drying of slides during the 
procedure. The fixed slides were first rehydrated in H2O, twice for 5 min and then equilibrated 
with 2.5 M HCl for 5 min. DNA was denatured to yield single strands by the incubation of 
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these slides with HCl for an additional 80 min at RT. After HCl treatment, the water in 
chamber was changed, and the slides were rinsed twice with PBS. This was followed by two 
short 5 min rinses with blocking solution. Then, slides were blocked for an additional hour at 
RT. Thereafter, slides were dried thoroughly to get rid of the blocking solution, and incubated 
with 150 µL of the primary antibodies for 1 h, at 37 °C. While rat anti BrdU recognized CldU, 
mouse anti IdU was directed against IdU. Both the antibodies were prepared at a dilution of 
1:500 in blocking solution. After this, slides were rinsed three times with PBS and fixed in 500 
µL 4% formaldehyde (prepared in PBS) at RT, for 10 min, and then rinsed once again with 
PBS. Then, blocking solution was added three times for 5 min each to prevent the unspecific 
binding by the secondary antibody. Slides were dried again, and 150 µL of fluorophore-
coupled secondary antibodies was added to the slides. Alexa-Fluor-555 goat anti rat and 
Alexa-Fluor-488 goat anti mouse were made at 1:250 dilution in blocking solution. Slides 
were left to incubate with secondary antibodies at RT for 2 h. Later, slides were rinsed twice 
with PBS, washed three times with blocking solution for 5 min each, and rinsed once again 
with PBS and ddH2O. Slides were mounted using one drop of H-1400 vectashield, and 
sealed from the sides with nail polish. Fluorescence microscopy was performed using a 63x 
objective in one experiment (Result 5.3 was obtained with a 63x objective), and a 40X 
objective was used for all other experiments.   
For each sample, at least twenty microscopic images were taken and nearly 500 structures 
were counted and analyzed from each experiment. Ongoing forks were measured for their 
lengths using Fiji, and the Cell Counter Plug-in from Fiji was utilized for counting the origin 
firing structures (Kurt De Vos, University of Sheffield, UK). The resulting data was further 
analyzed with Microsoft Excel and Graph Pad Prism.  
4.5 Statistical analysis 
Statistical analysis was carried out with Graph Pad Prism. Statistical significance values were 
determined using the unpaired, two-tailed student’s t-test. Significance was assumed for p-
values below 0.05. n.s. = not significant. n in figure legends indicates the number of 
independent experiments. Additionally, this was cross-checked by Mann-Whitney test. When 
measuring the lengths of DNA fibers using Image J, conversion factors used were: with a 
63X objective, the conversion factor used was 10 µm = 9.8 and with a 40X objective, the 
conversion factor used was 10 µm = 3.1. 
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5. Results 
5.1 Inhibition of MKP1, using BCI, accumulates phospho-H2AX in various 
cell lines 
In recent years, MKP1 has been established as a potential candidate responsible for chemo-
resistance in pancreatic cancer, ovarian cancer and lung cancer; owing to its high expression 
levels (see 2.8). Since many of the commonly used chemotherapeutic agents execute their 
actions by causing DNA damage, they also instigate the DNA damage response (DDR), 
orchestrated by various kinases and phosphatases. The present study aims to investigate 
the role of MKP1 in such a scenario via the usage of a commercially available small molecule 
inhibitor, BCI.HCL (2-benzylidene-3-(cyclohexylamino)-1-Indanone hydrochloride) (Molina, 
Vogt et al. 2009). BCI was able to arrest MKP1 in its least-active conformation; thereby 
blocking the ‘substrate-binding induced’ phosphatase activity. A wide variety of cancer cell 
lines were chosen for this purpose, namely U2OS (osteosarcoma), Jurkats (T-cell leukemia) 
and MiaPaCa-2 (pancreatic carcinoma).  While U2OS and MiaPaCa-2 were treated with 
DMSO or 5 µM BCI for 4 h, Jurkats were treated with 1 µM BCI for 3 h and subsequently 
harvested. The 3 h time point was chosen for Jurkats as they started undergoing cell death 
after 4 h of BCI treatment. Whole cell lysates were analyzed by immunoblotting for 
phosphorylated p38MAPK and DNA damage marker - phospho-histone 2AX (Ser 139) (or 
γH2AX). As expected, the levels of dually phosphorylated p38MAPK (designated as 
pP38MAPK Thr 180/Tyr 182) were increased, confirming the efficiency of BCI. 
Concomitantly, an accumulation of γH2AX was also seen (Fig. 5.1). Taken together, the 
above results suggest a close involvement of MKP1 in the DDR network. 
 
Figure 5.1 Accumulation of phospho-H2AX (S139) upon MKP1 inhibition using BCI. 
MKP1 activity was blocked in U2OS, MiaPaCa-2 and Jurkats using the pharmacological allosteric 
inhibitor, BCI. After treatment with the given concentrations of BCI or equal volumes of DMSO as a 
control for the indicated time points, cells were harvested; protein extracts were prepared and 
analyzed by immunoblotting using the indicated antibodies. Ponceau-S stain was used to check equal 
loading.  
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5.2 MKP1 inhibition impairs replication fork progression 
As the inhibition of MKP1 led to an accumulation of DNA damage even in the absence of any 
exogenous damaging agent (see 5.1), we were interested in elucidating the mechanistic 
details underlying this observation. One of the many reasons for such a response could be 
the existence of faulty replication, giving rise to spontaneous damage (Mazouzi, Velimezi et 
al. 2014). Hence, to evaluate replication kinetics, we used the DNA fiber assay as described 
in section 4.4. U2OS cells were selected as a model system for all the experiments due to 
their low levels of intrinsic DNA damage and convenience in handling. 
For the assay, cells were incubated with MKP1 inhibitor, BCI or DMSO for 1 h and later pulse 
labeled with thymidine analogs, 5-Chloro-2′-deoxyuridine (CldU, first label) and 5-Iodo-2′-
deoxyuridine (IdU, second label) for 30 min each, in the presence of DMSO or BCI (Fig. 
5.2A). Following this, cells were lysed; DNA was spread on glass slides, denatured and 
immunostained with antibodies against CldU (red) and IdU (green), which was then, 
visualized using fluorescence microscopy. This technique allowed us to calculate the rate of 
replication by measuring the uni-directional, ongoing replication structures (red-green) for 
their lengths using (Fig. 5.2D; see 4.4). The analysis exhibited a significant reduction of fork 
speed with BCI treatment when compared to the DMSO control (Fig. 5.2B). This effect was 
also clearly evident in the frequency distribution of CldU and IdU fork speeds, where the BCI 
exposed population had a higher percentage of forks with lower fork rates (Fig. 5.2C), 
shifting the histogram to the left with reference to DMSO. Furthermore, given that MKP1 is 
nuclear; such an effect at DNA replication seems highly plausible.  
DNA fiber assays can be conducted with siRNA mediated knockdowns of the protein, but 
have been shown to result in a steady state change of replication events as reported 
previously by Petermann and co-workers (Petermann, Woodcock et al 2010). Thus, we 
conducted experiments only using inhibitors for short periods of time that was able to induce 
profound changes, which could later be easily monitored.   
In conclusion, the above results strongly indicate a role of MKP1 in supporting replication fork 
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Figure 5.2 MKP1 inhibition reduces replication fork speed.  
(A) Labeling protocol for DNA fiber analysis. U2OS cells were pre-treated with 3 µM BCI or an equal 
volume of DMSO for 1 h. This was followed by pulse labeling with CldU or IdU for 30 min each, in the 
continuous presence of inhibitor. Both CldU and IdU were detected using specific primary antibodies. 
CldU was detected using red and IdU was detected using green secondary antibody.  
(B) Average of total replication fork speed (sum of CldU and IdU labeled track lengths) in cells treated 
with DMSO and BCI as described in (A) (n=3). Statistical analysis was done using students t-test, p-
values are indicated in the figures.  
(C) Histogram depicting the distribution of CldU and IdU replication fork speeds in DMSO and BCI 
treated cells (n=3). 
(D) Representative images of replication tracks after labeling according to A.  
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5.3 MKP1 inhibitor acts together with Gemcitabine to further reduce 
replication fork speed 
After observing that MKP1 inhibition interferes with replication, (see 5.2), we wanted to 
explore the function of this phosphatase under conditions of replicative stress induced by 
exogenous sources.  
In this view, we used the S-phase specific nucleoside analog, gemcitabine (2'-deoxy-2',2'-
difluorocytidine), which incorporates itself instead of cytidine into the replicating DNA, and 
thence leads to chain termination and fork stalling. Since both BCI and gemcitabine act by 
perturbing replication, we conducted DNA fiber experiments in their presence to examine 
these changes (experimental work done in collaboration with Dr. Ann Christin Parplys, 
Hamburg). Cells were treated as depicted in Fig. 5.3A and DNA fiber spreads were analyzed. 
As expected, in the single treatments of BCI and gemcitabine, there was a marked reduction 
in the replication fork speed. This was further reduced when the drugs were given in a 
combination treatment (Fig. 5.3B and D). Such a massive slow-down of replication raises the 
possibility of cells going into a prolonged S-phase arrest or pre-mature mitosis, either or both 
of which would ultimately result in cell death.  
In this experiment, since gemcitabine was added at the second label, for comparison 
between samples, ideally, only IdU track lengths should have been taken. However, in our 
experiments, we saw that the addition of gemcitabine also affects the CldU label, where they 
become shorter when compared to the control. Thus, we chose to calculate the total fork 
speed using CldU and IdU track lengths. This phenomenon is likely due to the instability of 
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Figure 5.3 BCI and Gemcitabine co-operate to further impair the progression of replication fork.  
(A) Labeling protocol for DNA fiber analysis. U2OS cells were pre-treated with 1 µM BCI or an equal 
volume of DMSO for 1 h and later labeled with CldU or IdU for 30 min each, in the presence of BCI or 
DMSO. 400 nM gemcitabine was added along with IdU.  
(B) Average of total replication fork speed (sum of CldU and IdU labeled track lengths) in cells treated 
as shown in (A) (n=3). Students t-test was used to evaluate significance of the data; p-values are 
displayed in the figures.  
(C) Representative images of replication tracks after labeling according to A.  
(D) Distribution of total replication fork speeds in the various conditions outlined above (n=3).  
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5.4 Inhibition of MKP1 differentially regulates checkpoint signaling 
DNA replication is a tightly regulated process engaging various proteins, some of which are 
also a part of the DDR signaling cascade. To understand the dynamics of MKP1 in 
replication and DDR, (5.1 and 5.2); we looked for the activation of certain checkpoint kinases 
which are known for their interplay in the same; namely, MAPKAPK2 (MAPK Activated 
Protein Kinase 2) and Chk1 (Checkpoint Kinase 1).  
MK2 is a Ser/Thr kinase (also called Chk3), phosphorylated at Thr 344 and activated by 
p38MAPK. Originally known to feature in the inflammatory response, it was only recently 
discovered to operate alongside ATR-Chk1 and ATM-Chk2 in DDR. Most prominently, a 
study from Köpper et al., showed that gemcitabine induced DNA damage relies on MK2 
activity to inhibit translesion synthesis. Chk1 is another canonical checkpoint kinase of the 
damage signaling axis closely associated with replication; whose inhibition decreases fork 
progression by promoting the firing of dormant origins (Petermann, Woodcock et al. 2010). 
Immunoblot analysis from a time course experiment with DMSO / BCI done in the presence 
of a pan-caspase inhibitor Z-VAD-FMK [to block the activation of DDR by caspases 
(Matsuura, Wakasugi et al. 2008)] revealed the phosphorylation of p38MAPK as early as 1 h 
after exposure to BCI. This was accompanied by the phosphorylation of Hsp27 (pHsp27 Ser 
82), a downstream substrate of MK2, which was used to assess MK2 activity (Fig.5.4A, lanes 
2,6,10). In contrast, Chk1 was not phosphorylated when cells were treated with BCI alone. 
This prompted us to check if there was any effect at all at the level of Chk1 activation. To that 
end, we used gemcitabine to induce Chk1 activation and subsequently monitored the 
phosphorylation status of Chk1. Remarkably; Chk1 was subjected to negative regulation by 
BCI, in the presence of gemcitabine. This resulted in a loss of its phosphorylation (at Ser 
317) and activity when both BCI and gemcitabine were combined (Fig. 5.4A, lanes 3 and 4; 7 
and 8; 11 and 12). We also checked for the activation of checkpoint kinase 2 (Chk2), which 
surprisingly, was also phosphorylated (pChk2 Thr 62) (Fig. 5.4B) in response to BCI. Unlike 
MK2 and Chk1, Chk2 has so far not been implicated in DNA replication, but is known to 
mediate cell cycle arrest during various stress conditions, including DNA damage. 
Collectively, this data indicates that MKP1, in addition to inactivating the stress response 
kinases - p38MAPK, JNK and ERK’s (see 2.8), also modulates the activity of other protein 
kinases like Chk1 and Chk2, which are involved in replication and DNA damage response 
signaling.  
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Figure 5.4 Activity of checkpoint kinases is subjected to differential regulation by MKP1. 
(A) U2OS cells were treated with 5 µM BCI, 500 nM Gemcitabine or an equal volume of DMSO in the 
presence of a pan-caspase inhibitor, Z-VAD-FMK (25 µM).  
(B) U2OS cells were treated with 5 µM BCI or an equal volume of DMSO in the presence of a pan-
caspase inhibitor, Z-VAD-FMK (25 µM) to block apoptosis.  
In both (A) and (B), protein extracts prepared after each of the indicated time points, were subjected to 
an immunoblot analysis with the antibodies mentioned in the figure. β-Actin served as a loading 
control.  
RESULTS                                                                                                                               54 
 
5.5 Activation of ATM and MK2, is responsible for replicative stress 
induced by MKP1 inhibition  
Continuing our quest to delineate the pathways responsible for the disturbed replication seen 
with MKP1 inhibition, we again employed the DNA fiber assay, this time inhibiting the kinases 
- MK2 and Chk2, both of which were activated in the first hour of BCI treatment (see 5.4). 
MK2 was inhibited using a chemical competitive inhibitor - MK2III, and Chk2 activity was 
abolished by the inhibition of its upstream sensor kinase - Ataxia telangiectasia mutated 
(ATM). To look for any rescue effects, cells were pretreated with DMSO, MK2III or KU55933 
(ATM inhibitor) for 30 min and later pulse-labeled with CldU and IdU in the presence of 
DMSO or BCI. MK2III / KU55933 / DMSO stayed on during the label as well (Fig. 5.5A and 
D). This was followed by cell lysis, and processed for DNA fiber spreads as described before. 
When MK2 was inhibited along with BCI, there seemed to be no rescue in the average of 
total fork speed (Fig. 5.5E and F). However, it is possible that only certain populations of 
replication forks are rescued. This will be statistically insignificant when averaged over a 
large number of forks. Thus, we analyzed the distribution of fork speeds between BCI and 
BCI+MK2III, where we found a slight difference between the two treatments (Fig. 5.5H, page 
56). Indeed, the percentage of forks with speeds between 1 kb/min and 1.2 kb/min was 
higher in the combination treatment as compared to the BCI treatment alone. Hence, MK2 
rescues the slowly progressing forks, albeit very mildly.  
Interestingly, the replication slow down caused by BCI was relieved by the simultaneous 
inhibition of ATM (p = 0.01) (Fig. 5.5B and C). This effect was also distinctly visible in the 
histograms depicting the distribution of total fork speeds (Fig. 5.5G, page 56). 
Complementing this finding was a decrease in the phosphorylation of H2AX in an 
immunoblot experiment (Fig. 5.5I lanes 2 and 4; page 57), where cells were pre-incubated 
for 30 min with KU55933, followed by treatment with BCI / DMSO in the presence of 
KU55933 for 4 h. The slight phosphorylation of H2AX seen with DMSO could be a result of 
cellular stress induced by the same. Z-VAD-FMK was added to the all the samples for the 
same reason as outlined in 5.4. Here, phospho-Chk2 (Thr 62) was used as a read out for 
ATM activity, which clearly disappeared upon treatment with KU55933. Consequently, we 
hypothesized that an active MKP1 negatively regulates the p38MAPK/MK2 and ATM/Chk2 
pathway to maintain the speed of elongating forks, adding a new dimension in the cascade 
linking phosphatases with DDR and replication. 
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Figure 5.5 Replicative stress induced by MKP1 inhibition is dependent on ATM, but not MK2.  
(A,D) Labeling protocol for DNA fiber analysis. U2OS cells were first pre-treated with 10 µM ATM 
inhibitor (KU55933) / an equal volume of DMSO in (A) or 10 µM MK2 inhibitor (MK2III) / an equal 
volume of DMSO in (D) for 30 min. This was followed by treatment with 3 µM MKP1 inhibitor (BCI) or 
an equal volume of DMSO for 1 h (both A and D) in the presence of DMSO / KU55933 (in A) or DMSO 
/ MK2III (in D). Later, cells received 30 min pulses of CldU and IdU in the continuous presence of the 
inhibitors as shown in (A) and (D). 
(B,E) Average of total replication fork speed (sum of CldU and IdU labeled track lengths) was 
calculated for cells treated as explained above (n=3). Student t-test yielded p-values which are shown 
in the figures.  
(C,F) Representative images of replication tracks.  
 
 




Figure 5.5 Continued. 
(G,H) Distribution of total replication fork speeds in the various conditions presented above (n=3).  
 
Carrying forward, we were determined to learn if the rescue in replication fork speed noticed 
with ATM inhibition was a result of a loss in ATM activity or Chk2 function. To this end, an 
immunoblot experiment was performed in a manner similar to the one outlined above, the 
only difference being the replacement of KU55933 with Chk2 inhibitor (Sc203885). Since 
pChk2 (Thr 68) accumulates in the presence of the Chk2 inhibitor Sc203885, this was used 
as a read out for Chk2 inhibitor efficiency (Sharma and Tepe 2004, Jobson, Lountos et al. 
2009). As opposed to the results obtained with KU55933, the inhibition of Chk2 along with 
BCI did not affect the phosphorylation status of H2AX (Fig. 5.5J, lanes 2 and 4). Using Chk2 
inhibitor with BCI in DNA fiber experiments would give much clearer insights along this line, 
but based on these findings, we can still postulate that active ATM and not Chk2, contributes 
to the replication defects observed upon MKP1 inhibition (Figure on the next page). 
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Figure 5.5 Continued. 
Chk2 activity is not required for the effects of MKP1 inhibition.  
(I) U2OS cells were exposed to 5 µM BCI with and without ATM inhibitor (KU55933) in the presence of 
Z-VAD-FMK for 4 h, and harvested for an immunoblot analysis against the above specified proteins. β-
Actin was used as a loading control. 
(J) Experiment was performed as outlined in (I), the only difference being the replacement of KU55933 
with Chk2 inhibitor Sc203885. Ponceau-S stain was used to check the efficiency of loading.  
 
5.6 MKP1 inhibition decreases origin firing, independently of ATM 
activity 
Replication fork speed and origin firing are inversely coupled processes. Under conditions of 
replicative stress, where fork progression is hampered, the dormant origins which are 
otherwise passively replicated by ongoing forks from their neighboring counterparts start 
firing, in order to compensate for the stalling and/or reduction in fork speed (see 2.5). So, 
besides analyzing the speed of replication upon MKP1 inhibition, we also estimated the level 
of origin firing by representing the first label origins (green-red-green) as a percentage of all 
red labeled structures (see 4.4). Strikingly, just like the rate of replication, the percentage of 
newly fired origins also showed a significant decrease with BCI treatment when compared to 
the DMSO control (Fig. 5.6A and C). Moreover, this effect remained unaltered even in the 
presence of KU55933; allowing us to suspect the existence of other MKP1 substrates 
controlling origin firing (Fig. 5.6B and D). 
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Figure 5.6 An ATM independent decrease in origin firing upon MKP1 inhibition.  
(A) Labeling protocol for DNA fiber analysis. After pre-treatment with 3 µM BCI or DMSO for 1 h, 
U2OS cells were kept in medium containing CldU+BCI / DMSO for 30 min and subsequently IdU+BCI 
/ DMSO for another 30 min. This was followed by cell lysis and immunostaining as described 
previously (n=6). 
(B) Labeling protocol for DNA fiber analysis. U2OS cells were first pre-treated with 10 µM ATM 
inhibitor (KU55933) or an equal volume of DMSO for 30 min. Afterwards, 3 µM MKP1 inhibitor (BCI) or 
an equal volume of DMSO for 1 h was added to the cells in the presence of KU55933 or DMSO 
(wherever appropriate). Inhibitors stayed on the cells while they were received CldU and IdU pulses 
for 30 min each. Cell lysis and immunostaining was done as above (n=3). 
(C) and (D) First label origins (green-red-green, sample figure shown in methods) were counted and 
quantified as a percentage of all red labeled structures, for the cells treated as outlined above. 
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5.7 Inhibiting MKP1 activity results in the loss of replication initiator 
kinase Cdc7 and MCM2 phosphorylation  
Origin firing is a spatio-temporally regulated event utilizing big-protein machineries, which 
includes ORC’s (Origin Recognition Complex), DNA replication factor - Cdt1, Cdc6 (Cell 
division cycle 6) and the ATP powered MCM2-7 complex (Mini-Chromosome Maintenance). 
These proteins assemble sequentially at the origins to form a pre-replicative complex (pre-
RC) during the G1 phase of cell cycle, but are still inactive. When cells enter S-phase, these 
proteins are phosphorylated by Cdk (Cyclin-dependent kinase) and DDK (Dbf4-Dependent 
Kinase), which then initiate replication (see 2.1.2). 
DDK is a protein complex consisting of cell division cycle 7-related protein kinase (Cdc7) and 
its regulatory partner Dbf4. Cdc7 phosphorylates and activates MCM helicases that are 
required for triggering replication initiation by facilitating DNA unwinding. One such 
phosphorylation site is Ser 53 of MCM2, which is a direct target of Cdc7 kinase in the G1-S 
transition (Montagnoli, Valsasina et al. 2006) Considering this, we analyzed the kinetics of 
Cdc7 and MCM2 phosphorylation upon MKP1 inhibition, via immunoblotting the whole cell 
lysates prepared from 2 h and 4 h BCI / DMSO treated cells. Remarkably, both Cdc7 levels 
and MCM2 phosphorylation disappeared upon BCI treatment (Fig. 5.7A) - a phenomenon 
which could explain the decreased rate of origin firing observed in 5.6.  
Supplementing this finding is the work of Montagnoli et al., where PHA 767491, a well-known 
inhibitor of Cdc7 kinase, was shown to decrease the rate of origin firing without affecting the 
replication fork speed. Additionally, in our experiments we used two different inhibitors 
against Cdc7- PHA 767491 and XL413 (Montagnoli, Valsasina et al. 2008, Koltun, Tsuhako 
et al. 2012), and looked for the activation of certain proteins in the DNA damage and stress 
response pathways. γH2AX was used as a read out for DNA damage whereas accumulation 
of pHsp27 was used for detection of stress response. Phospho-MCM2 Ser 53 was 
additionally stained to control for the potency of Cdc7 inhibitors. The immunoblot showed a 
gradual decrease in the phosphorylation of MCM2 over time, with the effects observable after 
6 h of treatment, thus confirming Cdc7 inhibition (Fig. 5.7B-1 and B-2). In parallel, we could 
also detect the phosphorylation of H2AX and Hsp27, very similar to the effects obtained with 
BCI treatment. It should be noted that with PHA767491 there is a loss of Cdc7 observed after 
24 h of treatment. This is an unexplained phenomenon also seen by Montagnoli et al. 
Although pChk2 was not checked, nonetheless, it will be very interesting to look into its 
activation pattern as well. In totality, these observations point towards a possible link 
between MKP1 and Cdc7 to regulate replication initiation. 
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Figure 5.7 MKP1 inhibition leads to a decrease in Cdc7 levels and MCM2 phosphorylation. 
(A) U2OS cells were incubated with 5 µM BCI or an equal volume of DMSO for 2 h and 4 h, in the 
presence of Z-VAD-FMK. Cells were harvested after each time point, and protein extracts were 
analyzed by immunoblotting using the indicated antibodies. β-Actin was used as a loading control. 
Asterix (*) indicates the protein of interest. 
(B) U2OS cells were treated with 1, 5 and 10 µM Cdc7 inhibitors, XL413 (B-1) or PHA767491 (B-2) for 
the indicated time points and harvested for immunoblot. An equal volume of DMSO corresponding to 
10 µM of the inhibitor was used as a control. Proteins were detected using the indicated antibodies. β-
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5.8 Proteasome degradation or mRNA regulation are not responsible for 
the loss of Cdc7 after MKP1 inhibition 
Decreased protein levels are mainly due to a loss in mRNA copies or degradation of the 
protein itself. To test which out of the two is responsible for the apparent reduction of Cdc7 
levels seen with MKP1 inhibition (see 5.7), cells were treated with DMSO or BCI in the 
presence of Z-VAD-FMK, for 1 h, 2 h and 4 h; RNA was isolated and a quantitative RT-PCR 
was done using primers specific to Cdc7 (experiment conducted with Christin Kellner). This 
allowed us to measure the Cdc7 mRNA levels, which remained unchanged with BCI 
treatment (Fig. 5.8A). Thereupon, we exposed the cells to a proteasome inhibitor - MG132 
along with DMSO / BCI and analyzed total protein levels. To our surprise, this as well did not 
aid in recovering the lost Cdc7 (Fig. 5.8B, lanes 2 and 4; 6 and 8).  
As there are additional levels of regulation at the step of translation, where mRNA’s can be 
modified to block protein synthesis, and post-translation, where proteins are modified by the 
addition of small groups (phosphate, ubiquitin, SUMO etc.) that can mask its epitope required 
for antibody recognition; this ambiguous loss of Cdc7 could be a result of such a modification 
and thus still be explored further.  
Co-incidentally when we examined Cdc7 levels in the BCI and ATM inhibited samples, it still 
remained lost (Fig. 5.8C, lanes 2 and 4; 6 and 8). This was in accordance with our DNA fiber 
data where origin firing was unaffected in the presence of KU55933 (see 5.6).  
Summarizing the results above, we can state that MKP1 inhibition reduces the replication 
fork rate by inactivating the two kinases, MK2 and ATM. Additionally, Cdc7 is also down-
regulated, which may explain the reduced origin firing seen when MKP1 is blocked. 
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Figure 5.8 Disappearance of Cdc7 upon MKP1 inhibition is not due to a loss of mRNA or 
protein. 
(A) U2OS cells were treated with 5 µM BCI or an equal volume of DMSO for 1 h, 2 h and 4 h in the 
presence of Z-VAD-FMK. After each time point, total RNA was extracted using TRIzol and gene 
expression of Cdc7 was analyzed via qRT-PCR. GAPDH was used as the reference gene for 
normalization. 
(B) U2OS cells were treated with 5 µM BCI or an equal volume of DMSO in the presence of 20 µM 
proteasome inhibitor - MG132 for 2 h and 4 h.  
(C) U2OS cells were treated with 5 µM BCI and 10 µM ATM inhibitor KU55933 for the indicated time 
points. In both (B) and (C) cells were subsequently harvested for protein and analyzed by immunoblot 
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5.9 Longer exposure to BCI or reduction of MKP1 levels leads to 
apoptosis 
It is a well-known fact that prolonged replicative stress can result in collapsed replication 
forks thereby setting off the alarms for apoptosis - a programmed set of signaling events 
brought about by the action of certain specific proteases, called caspases, culminating in cell 
death. To shed some light on this in the context of MKP1 inhibition; we did a simple 
immunoblot after treating cells with BCI (or DMSO as control) for longer hours and stained 
for the apoptotic markers - caspase-3 and PARP-1. Caspase-3 is a cysteine-aspartic 
protease existing in an inactive zymogen state in the absence of apoptotic stimuli. Upon 
receiving the appropriate signal, caspase-3 is cleaved into its active form, which is then 
responsible for chromatin condensation and DNA fragmentation that accompanies the 
morphological changes seen during apoptosis. On the other hand, PARP-1 (Poly [ADP-
ribose] polymerase 1) is a DNA repair protein that carries out its function by modifying its 
acceptor by Poly-ADP-ribosylating it. This also undergoes cleavage and hence inactivation at 
the time of apoptosis.  As predicted, 12 h of BCI treatment led to the activation of caspase-3 
and inactivation of PARP-1, proving that extended MKP1 inhibition can indeed be cytotoxic 
(Fig. 5.9A). Furthermore, identical results were obtained with a transient depletion of MKP1 
from the cells using siRNA mediated knockdown approach, thus re-affirming our inhibitor 
data (Fig. 5.9B).  
 
Figure 5.9 MKP1 knockdown or BCI treatment for long hours leads to apoptosis. 
(A) U2OS cells were treated with 5 µM BCI 12 h and 24 h and harvested after each time point. Whole 
cell lysates were subjected to an immunoblot assay and proteins shown in the figure were detected 
using corresponding antibodies. Asterix (*) indicates the protein of interest. 
(B) U2OS cells were reverse transfected with a non-targeting siRNA or siRNA specific to MKP1 
(designated as s4363, 10 nM) using lipofectamine and harvested after 48 h for immunoblot analysis. 
Asterix (*) indicates the protein of interest. Hsc70 was used as a loading control in both (A) and (B). 
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5.10 MKP1 knockdown is accompanied by a caspase independent 
degradation of an anti-apoptotic protein, Mcl-1  
While replicative stress can be one reason for apoptosis observed with MKP1 
inhibition/depletion, we were eager to find out if this was the only culprit. To reflect upon this, 
we used a candidate approach to look for any apoptotic protein that might be regulated by 
MKP1. For this and all following experiments, we carried out transient knockdown of MKP1 
as it ensured complete depletion of the protein and at the same fit the longer time frame 
criteria for observing apoptosis. The protein lysates were subsequently analyzed via 
immunoblot for various pro-apoptotic as well as anti-apoptotic proteins (data not shown). A 
non-targeting siRNA was used as a control. One interesting candidate was an anti-apoptotic 
protein Mcl-1 (Myeloid cell leukemia 1); which became nearly undetectable upon MKP1 
knockdown (Fig. 5.10A, lanes 1 and 2). 350 amino acids long, this protein belongs to the Bcl-
2 family of pro / anti-apoptotic regulators and is localized to the mitochondria where it binds 
to and inactivates the pro-apoptotic factors, e.g. Bim and Bax (see 2.5). 
Since Mcl-1 is also subjected to cleavage by caspases, its disappearance observed with 
MKP1 depletion, could be a manifestation of apoptosis rather than the cause itself (Herrant, 
Jacquel et al. 2004, Weng, Li et al. 2005, Hu, Dang et al. 2011). Therefore, we performed a 
knockdown for 48 h this time in the presence of a pan-caspase inhibitor, Z-VAD-FMK. This 
however did not influence our results, and the loss of Mcl-1 still remained demonstrating that 
Mcl-1 degradation is not a consequence of apoptosis in this context (Fig. 5.10A, lanes 3 and 
4). 
These findings motivated us to study the mechanics of Mcl-1 regulation, and in this reference 
we checked if the loss of Mcl-1 was dependent on the proteasome machinery (Nijhawan, 
Fang et al. 2003, Derouet, Thomas et al. 2004). Therefore, the knockdown experiments were 
performed along with a proteasome inhibitor - MG132, which was added in the last 4 hours of 
transfection. This approach rescued the lost levels of Mcl-1 (Fig. 5.10B) and led us to believe 
that MKP1 might act to protect Mcl-1 from degradation, thereby maintaining a fine balance 
between apoptosis and survival. 
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Figure 5.10 Anti-apoptotic protein Mcl-1 is degraded independent of caspase activity upon 
MKP1 depletion. 
(A) U2OS cells were reverse transfected with 10 nM MKP1 or non-targeting siRNA using 
lipofectamine. 24 h after transfection, a pan-caspase inhibitor Z-VAD-FMK was added, and left on for 
an additional 24 h.  
(B) U2OS cells were reverse transfected with 10 nM MKP1 siRNA for 48 h. A non-targeting siRNA was 
used as a control. Proteasome inhibitor, MG132 (20 µM), was added in the last 4 hours of transfection. 
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5.11 Apoptosis upon MKP1 depletion can be partially rescued by Mcl-1 
over-expression 
To confirm whether Mcl-1 degradation was indeed specifically responsible for cell death upon 
MKP1 knockdown, we over expressed Mcl-1 to see if this would rescue the detected 
phenotype. Cells were first reverse transfected with non-targeting or MKP1 siRNA and 24 h 
later, forward transfected with an empty or Mcl-1 over-expressing plasmid for an additional 
24 h. This was followed by protein extract preparation and immunoblot analysis.  
As shown in Fig. 5.11 (lanes 3 and 4), Mcl-1 over-expression was detectable as expected. 
Bringing back the levels of Mcl-1 proved beneficial for the cells, as now the cells lacking 
MKP1 had much lower levels of cleaved PARP-1 (Fig. 5.11, lanes 2 and 4). Although 
restoring Mcl-1 did not completely help in cellular survival; one should not rule out the 
existence of replicative stress, which can still contribute to apoptosis in cells deprived of 
MKP1. 
                           
Figure 5.11 Apoptotic effects of MKP1 knockdown are partially rescued by over-expression of 
Mcl-1. 
U2OS cells were reverse transfected with 10 nM non-targeting or MKP1 siRNA using lipofectamine. 24 
h after transfection, cells were re-transfected with a Mcl-1 over-expression vector- pcDNA3.1 hMcl-1 
(375 nG) or pcDNA3 empty vector for 4 h. After this media was changed and cells were allowed to 
grow in full medium for an additional 20 h and later harvested for an immunoblot analysis. Hsc70 was 
used as a loading control.  
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5.12 MKP1 interacts with Mcl-1 under unstressed conditions 
Nuclear MKP1 regulates the activity of mitochondrial Mcl-1. How is this possible, unless they 
come in close proximity to each other? To answer this question, we took the classical 
approach of using in vivo complex-immunoprecipitation to look for an interaction between 
these proteins. U2OS were transfected with a plasmid encoding the cDNA of myc-DDK 
tagged MKP1 or FLAG-Mcl-1 (Morel, Carlson et al. 2009). When we pulled down Mcl-1 in the 
cell lysate using the anti-Mcl-1 antibody, we precipitated MKP1 as well in those samples 
which were co-transfected with both the plasmids (Fig. 5.12). This was not the case when 
cells were transfected with MKP1 vector alone. This interaction was further re-enforced by a 
reverse IP, where MKP1 was pulled down using an anti-myc antibody in the cell lysate and 
Mcl-1 was co-immunoprecipitated in a similar experimental setting as described above 
(experiment conducted with Christin Kellner). Even though this is not on an endogenous 
level, the presence of an interaction itself, strongly suggested that Mcl-1 is subjected to direct 
regulation by MKP1. 
 
Figure 5.12 MKP1 interacts with Mcl-1 in an in-vitro co-immunoprecipitation assay. 
U2OS cells were transfected for 24 h with pcDNA3 empty, pCMV-Myc-DDK-hDUSP1 (alias MKP1), 
and pCMV-Flag-Mcl-1 over-expressing plasmids, using lipofectamine 2000, as indicated in the figures. 
Cells were harvested for Co-IP and pull down was done with the antibodies indicated in the figures. 
(Top) Pull down was done with Mcl-1 antibody and IgG was used a control. (Bottom) Pull down was 
done with Myc antibody and β-Gal was used as a control in this case. After the pull down and several 
washing steps later, the protein lysates were subjected to an SDS-PAGE, followed by immunoblotting. 
Blots were probed with the antibodies as indicated in the figures. 
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6. Discussion        
 
DNA is the storehouse of genetic information, with its sequence dictating the basis of all life. 
This makes it essential for cells to protect their DNA from a wide range of exogenous and 
endogenous genotoxic insults. Cellular DNA damage response tries to achieve this by 
activating a highly coordinated set of signaling events, which ensures genomic stability and 
facilitates DNA repair. This prevents DNA mutations that could result in uncontrolled cellular 
proliferation and tumor formation. DDR has long been known as a kinase dominated 
network, and only the last decade of work has witnessed a role for phosphatases, emerging 
in the same.  
To further explore this area of research, we investigated the contribution of a dual-specificity 
phosphatase, MKP1, in DDR. We found that a loss of MKP1 activity is sufficient to 
accumulate phospho H2AX in various cancer cells lines. Importantly, this was seen in the 
absence of any exogenous DNA damaging agent. Thus, we speculated a defect in 
replication kinetics to be responsible for this kind of spontaneous DNA damage observed 
with MKP1 inhibition. Indeed, replication fork speed and origin firing were significantly 
reduced in the absence of MKP1. Additionally, MKP1 inhibition further decreased the 
replication fork rate in the presence of a nucleoside analog, gemcitabine. Furthermore, the 
impaired fork progression caused by MKP1 inhibition was dependent on the activity of the 
replication checkpoint kinases, MK2 and ATM. While MK2 is known to inhibit replication by 
inhibiting translesion synthesis, the role of active ATM in promoting replicative stress has not 
yet been described. Besides this, MKP1 inhibition was also accompanied with the loss of 
Cdc7 kinase, a replication initiator protein which is required for origin firing. In addition to its 
effects on DNA replication, MKP1 is also essential for cellular survival. MKP1 interacts with 
an anti-apoptotic protein, Mcl-1, and protects it from getting degraded. This might be required 
for maintaining a fine balance between pro-survival and pro-apoptotic proteins, to avoid cell 
death in the absence of stress stimuli.  
Based on our studies, we have identified that MKP1 is necessary for promoting DNA 
replication both in the presence and absence of external stress stimuli. This may be essential 
to prevent replicative stress arising from the accumulation of irreparable, spontaneously 
stalled replication forks. Since certain phosphatases like PP2A (Protein Phosphatase 2A) 
and PP1 (Protein Phosphatase 1) are known to regulate DNA replication, the involvement of 
MKP1 in the same seems conceivable (Lin, Walter et al. 1998, Petersen, Chou et al. 2006, 
Dave, Cooley et al. 2014). Furthermore, many previous findings have only reported the 
inactivation of JNK by MKP1, to be responsible for preventing cell death (Sanchez-Perez, 
Martinez-Gomariz et al. 2000, Chattopadhyay, Machado-Pinilla et al. 2006, Takeuchi, Shin-
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ya et al. 2009). With our data, we demonstrate a direct regulation of the Bcl-2 family member, 
Mcl-1, upon MKP1 inhibition (Fig. 6.1). 
 
Figure 6.1 A hypothetical model representing the role of MKP1 in replicative stress and cell 
survival. 
MKP1 inhibits the p38MAPK/MK2 pathway and the kinase ATM, to maintain normal replication fork 
rates and avoid replicative stress. Additionally, MKP1 also maintains stable levels of Cdc7 and 
promotes replication initiation. Besides this, Mcl-1, an anti apoptotic protein is also protected from 
proteasomal degradation by interaction with MKP1, promoting cellular survival.  
  Activation 
             Inhibition  
Solid lines indicate a direct regulation and dashed lines indicate a possible direct regulation. 
 
While the effects of MKP1 activity loss are very prominent, the mechanisms are not so clear.  
Does MKP1 directly regulate the activity of ATM? Or is it because of some intermediate 
factors? How are Cdc7 and Mcl-1 protected by MKP1 from being lost? How does MK2 
participate in this context? These are some open questions that arise from our findings, 
which we will discuss in the subsequent sections. 
6.1 MK2 in controlling replication events upon MKP1 inhibition 
In our studies, MKP1 inhibition impaired replication fork progression and reduced the 
percentage of origin firing significantly (see 5.2 and 5.6). This was accompanied by the 
activation of MKP1 substrate, p38MAPK, which in turn phosphorylated its downstream target, 
MK2. Previous research has shown that gemcitabine-induced replication fork slowing relies 
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on the activity of MK2 to inhibit TLS polymerases (Kopper, Bierwirth et al. 2013). This 
motivated us to check if activated MK2 was responsible for the replication defects observed 
with MKP1 inhibition, as well. Strikingly, the hindered fork progression in our system seemed 
to be only partially dependent on MK2 activity (see 5.5). However, it should be noted that the 
changes observed here using fiber assays, were based on short term treatments of 
approximately 1-2 h. Thus, it is possible that during such a short time, TLS is only partly 
inactivated perhaps by a post translational modification; that does not generate very 
profound effects on replication (Köpper 2013). This technical detail gave us room to 
speculate the existence of a larger contribution from MK2, perhaps at the later stages of 
checkpoint activation. Indeed, preliminary immunoblot analysis performed with simultaneous 
inhibition of MK2 and MKP1 for 24 h, partially rescued the accumulation of MKP1 inhibition-
induced, DNA damage (γH2AX) (Appendix, Fig. 7.1, lanes 2 and 4). This result suggests that 
MK2 might as well be functional in DNA replication as a late-checkpoint kinase. Still, we need 
to confirm this hypothesis by conducting DNA fiber experiments with longer periods of 
inhibitor treatments (e.g. 24 h). Nevertheless, supporting this argument is the work from 
Reinhardt and group, who have previously reported such a late activation of MK2 for the 
maintenance of a prolonged DNA damage checkpoint (Reinhardt, Hasskamp et al. 2010). 
Additionally, MK2 is known to phosphorylate and inactivate the Cdc25 phosphatases, which 
are positive regulators of cyclin-Cdk2 complexes. As active cyclin-Cdk complexes are 
required to initiate origin firing by phosphorylating MCMs (see 2.1.2), such an activation of 
MK2 can explain the reduced origin firing seen upon MKP1 inhibition. Thus, monitoring origin 
firing in DNA fiber assays would provide us with more insights on this aspect. Moreover, 
examining the status of Cdc25A and Cdk2 (Cdk2pTyr15) in immunoblots, will provide us with 
answers for the molecular basis of the same. In conclusion, based on our results, we can 
postulate that MKP1 inhibition activates MK2 that induces a mild replicative stress, perhaps 
by inhibiting TLS polymerases. 
6.2 ATM: Deciphering the code in replication fork progression 
If the reduced fork rate upon MKP1 inhibition is not completely dependent on MK2; then what 
are the other reasons for observing such an effect? While seeking an answer to this 
question, we identified the kinase ATM, whose activation was also responsible for mediating 
the effects we observed (see 5.5). This result immediately posed two new questions, firstly, 
how would MKP1 inhibition promote ATM activity? And secondly how does ATM act to inhibit 
fork progression?  
While protein phosphatases Wip1 and PP2A are known to inactivate ATM, MKP1 has not 
been reported so far to dephosphorylate this kinase (Goodarzi, Jonnalagadda et al. 2004, 
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Shreeram, Demidov et al. 2006, Goodarzi, Douglas et al. 2007). Besides, being a Thr/Tyr 
specific phosphatase, the likelihood of MKP1 directly dephosphorylating ATM might be slim 
as this kinase is phosphorylated at Ser residues during activation (Ser 1981, Ser 1893 and 
Ser 367) (Kozlov, Graham et al. 2011). However, we cannot completely rule out the 
existence of a possible direct interaction between MKP1 and ATM. This interaction might 
facilitate the dephosphorylation and inactivation of ATM in unstressed conditions, thus 
preventing the untimely activation of checkpoint signaling. A co-immunoprecipitation assay in 
the presence and absence of BCI would give us more details into this aspect of MKP1 
regulation of ATM.  
Along with a possible direct interaction; we can also presume that ATM activation is a 
secondary effect of MKP1 inhibition. As mentioned previously one cannot set aside the 
participation of MK2 in regulating replication progression (see 6.1). Therefore, we can 
speculate that the replicative stress created by an activated MK2 might act as an additional 
trigger for ATM activation. Indeed, Olcina and co-workers have observed the activation of 
ATM in response to hypoxia-induced replicative stress. Since ATM is majorly known to be 
responsive against DNA damage arising from double stranded breaks, this piece of literature 
supports our results which also indicate a role for ATM in replicative stress (Olcina, Foskolou 
et al. 2013). Thus, if our theory with MK2 as an additional initiator for impaired replication 
holds true, triple inhibition with MKP1, MK2 and ATM would completely rescue the MKP1 
inhibition-induced, down-regulation of fork speed. This can also be supplemented by an 
immunoblot experiment, where ATM phosphorylation (Ser 1981) can be monitored.  
This makes way for our second question, how would ATM after activation, inhibit a 
progressing fork? During replicative stress, ATM acts to stabilize replication forks by 
facilitating chromatin remodeling and DNA repair (Costanzo, Robertson et al. 2000, Falck, 
Mailand et al. 2001, Groth, Lukas et al. 2003, Trenz, Smith et al. 2006, Olcina, Foskolou et 
al. 2013). However, our observations with ATM are pointing in the opposite direction, where 
we observe replicative stress as a consequence of ATM activation. How can we explain this 
phenomenon where ATM activation slows replication?  
Since DNA helix unwinding is one of the crucial steps in fork elongation, it is convenient to 
assume that the MCM2-7 complex might be subjected to regulation by ATM. Infact, MCM2 
and MCM3 are known to be phosphorylated by ATM at Ser 108 and Ser 535 respectively, 
after DNA damage (Cortez, Glick et al. 2004, Yoo, Shevchenko et al. 2004). Even though the 
functional consequence of such a phosphorylation is presently unclear; in the work 
conducted by Yoo et al., phosphorylation of Xenopus MCM at Ser 92 (Ser 108 in 
mammalians) inhibited DNA replication. Thus, we can presume the presence of such an 
inhibited MCM complex to mediate the effects seen due to ATM activation in our system.  
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Possible additional link between ATM and replication could be certain proteins that 
negatively regulate fork progression. One such candidate is called Timeless alias Tim. 
Originally identified as a homologue to the drosophila TIMELESS gene product, involved in 
controlling circadian rhythm; Tim, along with its partner protein, Tipin (Tim interacting 
protein), was soon shown to be engaged in replication and cell cycle checkpoint response 
(Unsal-Kacmaz, Mullen et al. 2005, Chou and Elledge 2006, Yoshizawa-Sugata and Masai 
2007, Smith, Fu et al. 2009). In 2007, Kacmaz and colleagues reported a 50% reduction of 
DNA synthesis in undamaged, Tim depleted cells (Unsal-Kacmaz, Chastain et al. 2007). In-
vitro experiments using purified Tim showed an interaction of Tim with the DNA polymerases 
– pol α, pol ε and pol δ, which stimulated the polymerase activity. This provided a potential 
explanation for the reduced fork speeds seen in Tim depleted cells (Aria, De Felice et al. 
2013, Cho, Kang et al. 2013).  
Despite lack of published reports on the existence of post translational modifications on Tim, 
protein sequence analysis using phosida (www.phosida.com) and phosphosite plus scan 
(www.phosphosite.org)  reveal the presence of putative ATM/ATR phosphorylation motifs 
(i.e. ‘SQ/TQ’ motifs) on Tim - IPAKLS1087PT1089QLRRAAA (Highlighted grey portion shows 
the SQ/TQ motif). Therefore, it is conceivable that a negative regulation of this complex by 
ATM might also contribute to the replication impairment seen with MKP1 inhibition. To test if 
Tim-Tipin complex contributes to the effects seen in our system, a DNA fiber experiment 
using MKP1 inhibitor, BCI, in cells depleted of Tim-Tipin can be carried out and analyzed for 
replication fork speeds. In such an experiment one would expect the BCI treated and the 
Tim-Tipin depleted samples to show reduced fork speeds. And, if our assumption holds true, 
the addition of BCI to a Tim/Tipin depleted sample would not have any further down-
regulatory effect on replication fork speed.  
Moreover, the absence of Tim-Tipin complex has other functional consequences besides 
affecting DNA replication. This includes a loss of Chk1 phosphorylation by ATR in Tim or 
Tipin depleted cells, challenged with DNA damaging agents (Errico, Costanzo et al. 2007, 
Kemp, Akan et al. 2010). This piece of information fits well with our observations where a 
loss in Chk1 phosphorylation with MKP1 inhibitor and Gemcitabine, was not accompanied by 
a reduction in ATR activity or Claspin. This suggests that Chk1 regulation may be a 
consequence of a loss in Tim-Tipin activity (Appendix, Fig. 7.2, lanes 2 and 4; 6 and 8). Such 
a down-regulation of Chk1 activity can also result in inhibited fork progression (Ge and Blow 
2010, Petermann, Woodcock et al. 2010).  
Additionally, one could also imagine other components of the replisome associated with the 
progressing fork to be potential ATM substrates. Indeed, a large scale proteomic analysis 
done by the group of Stephan Elledge, reported an overwhelming - 700 phosphorylated 
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substrates of ATM and ATR in response to DNA damage. Of these, 46 proteins were 
involved in DNA replication, recombination and repair (Matsuoka, Ballif et al. 2007). Later, 
Gamper et al., in 2010 identified an interaction between ATM and PCNA which positively 
regulated DNA polymerase δ and stimulated DNA synthesis (Gamper, Choi et al. 2012). 
Even though our data is incompatible with this particular finding, the presence of other 
putative ATM substrates which could be negatively regulated can still be considered.  
Thus, in reference to our results we can speculate that a loss in MKP1 activity directly and 
indirectly (via MK2) stimulates ATM activity, which in turn inhibits DNA synthesis. This is 
possibly mediated by the various mechanisms mentioned above – phosphorylation of MCMs, 
loss of Tim/Tipin complex etc. However, the participation of these mechanisms in mediating 
our effects still needs to be verified. To further confirm our findings about ATM in DNA 
replication, we could also use a Wip1 inhibitor, to activate this kinase. Such an experiment 
will help us to learn if this negative role of ATM is only specific for MKP1 inhibition or if it is 
more universal.  
Another interesting dimension to pursue will be the fate of these slowly replicating forks. 
Intuitively, one can imagine that these forks might stall, collapse or restart in the longer run. 
To monitor which is a likelier event to happen, we can quantify the percentage of stalled 
replication forks from a DNA fiber experiment, where cells are treated with MKP1 inhibitor for 
a long duration of time (see 4.4). Alternatively, since stalling of replication forks leaves 
behind long stretches of ssDNA, we can conduct a non-denaturizing BrdU uptake 
experiment, followed by immunofluorescence to calculate the percentage of ssDNA. Here, 
antibodies will be able to detect BrdU only in the open regions which have been created by 
the excessively unwound DNA near stalled forks. 
A variation of the DNA fiber assay can be performed to check collapse/restart of stalled forks 
– here, after pre-incubation of the cells with MKP1 inhibitor; the first label will be applied. The 
cells will be left to recover in an inhibitor-free medium for a specific period of time, after which 
the second label will be applied. If replication forks collapse after treatment, second label will 
not be incorporated, thus giving us a measure of the collapsed forks (Petermann, Orta et al. 
2010). In our studies, since long periods of MKP1 inhibitor treatment results in cell death, the 
probability of stalled forks collapsing seems higher.  
6.3 The disappearance of Cdc7 
MKP1 inhibition did not only affect progressing forks, but also inhibited replication initiation. 
As described in 6.1, while it remains to be seen if the reduction in origin firing upon MKP1 
inhibition is dependent on MK2, we found out an additional replication initiation regulator, 
Cdc7 kinase, to be down-regulated after MKP1 inhibition. While this result looked promising 
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initially, subsequent experiments done to verify this apparent down-regulation were 
inconclusive. This disappearance of Cdc7 seemed to be independent of proteasomal 
degradation or a loss in protein expression. To rule out the possibility of an unspecific binding 
by the antibody, a different clone was used that also yielded identical results (Appendix, Fig. 
7.3). However, in reference to our mRNA expression studies, it should be noted that our data 
had high standard deviations, indicating the prevalence of some technical issues. Hence, the 
possibility of a down-regulation in Cdc7 expression upon MKP1 inhibition should not be 
completely negated.  These results need to be verified by using different primer pairs as well. 
Moreover, the phosphorylation of MCM2 at Ser 53, which is mediated by Cdc7, is lost upon 
MKP1 inhibition, suggesting the involvement of Cdc7 in our system.  
Co-incidentally, while performing MKP1 inhibition experiments in p53 deficient (HCT p53 -/-), 
p53 mutant (MiaPaCa-2) and p53 wt (HCT 116 p53 +/+) cell lines, we observed that Cdc7 
and MCM2pS53 status, remains unchanged in both p53 null and mutant cell lines. On the 
other hand, p53 wt HCT cells showed a similar phenotype to that observed with U2OS cells, 
though not so profound. Strikingly, p53 was up-regulated upon MKP1 inhibition in the 
HCT116 p53 +/+ cells, suggesting the involvement of p53 in Cdc7 down-regulation 
(Appendix, Fig. 7.4). Supporting this belief is the inverse co-relation observed between p53 
status in tumors and Cdc7 expression (Bonte, Lindvall et al. 2008, Wang and Simon 2013).  
Thus, this axis of Cdc7 regulation can be investigated further. One way to delineate this 
pathway would be to use MKP1 inhibition in U2OS cells transiently depleted of p53, and then 
look for Cdc7 levels.  
Alternatively, Cdc7 might be phosphorylated upon MKP1 inhibition that masks the epitope of 
antibody binding. This might be a reason why the band intensity in these treated samples, 
appears weaker. Indeed, Cdc7 has four putative Cdk phosphorylation sites of which one 
residue, Thr 376, was found to be phosphorylated by Cdk/cyclinE in an in-vitro co-
immunoprecipitation assay (Masai, Matsui et al. 2000). Even though this observation is in 
disagreement with our results as we would expect a decreased Cdk activity upon MKP1 
inhibition, this does not rule out the possibility of a phosphorylation event existing.  
Besides regulating origin firing, Cdc7 has also been reported to interact with and 
phosphorylate the p150 subunit of CAF1 (chromatin assembly factor-1). CAF1 is a histone 
chaperone which binds histones and assists nucleosome formation during DNA synthesis 
(Smith and Stillman 1989, Kaufman, Kobayashi et al. 1995, Verreault, Kaufman et al. 1996). 
The phosphorylation by Cdc7 promotes the association of CAF1 with PCNA, thereby 
targeting it to sites of DNA replication (Gérard, Koundrioukoff et al. 2006). Hence, we can 
presume that upon MKP1 inhibition, the loss of Cdc7, might also affect CAF1 and chromatin 
assembly.  
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Additionally, Cdc7 has also been implicated in regulating the replication checkpoint, mainly 
involving the ATR-Chk1 pathway. Previous studies have shown its requirement in the 
activation of Chk1 in hydroxyurea (DNA synthesis inhibitor) treated cells (Kim, Kakusho et al. 
2008). Recent work by Rainey et al., suggests that Cdc7 activity is also essential for 
maintaining interactions between Claspin and certain members of the replisome including 
MCMs (Rainey, Harhen et al. 2013). What is more attractive is the positive regulation of 
translesion synthesis by Cdc7. The Cdc7/Dbf4 complex phosphorylates Rad 18, which 
promotes its interaction with Pol η and recruits it to the sites of stalled replication forks (Day, 
Palle et al. 2010, Vaziri and Masai 2010). Thus, a down-regulation of Cdc7 upon MKP1 
inhibition, can affect not only DNA replication, but also checkpoint response and repair; 
making it an interesting area to explore further.   
6.4 Keep them close for survival: MKP1 and Mcl-1  
In addition to protecting cells from spontaneously arising replicative stress, our data suggests 
that MKP1 promotes cellular survival by safe-guarding an anti-apoptotic member of the Bcl2 
family, Mcl-1, from proteasomal degradation. By doing so, a balance between the pool of 
pro-apoptotic and anti-apoptotic proteins is maintained, and cellular survival persists.  What 
remains to be understood is how MKP1 being a phosphatase regulates Mcl-1.  
As a first step towards learning this, we looked for a possible interaction between these 
proteins, which was clearly evident in the in-vitro co-immunoprecipitations using over-
expression plasmids (see 5.12). This data needs to be confirmed in the native system as 
well. Besides this, localization studies will give us better insights into the dynamics of MKP1-
Mcl-1 interaction, as both of these proteins are found in cytosol, nucleus and mitochondria 
(Yang, Kozopas et al. 1995, Akgul, Moulding et al. 2000, Fujise, Zhang et al. 2000, 
Leuenroth, Grutkoski et al. 2000, Jamil, Sobouti et al. 2005, Wu, Zhang et al. 2005, 
Chattopadhyay, Machado-Pinilla et al. 2006, Thomas, Lam et al. 2010, Candas, Lu et al. 
2014). 
Given that they interact with each other, how does MKP1 protect Mcl-1 from degradation? 
What could be the molecular mechanism underlying the same? Mcl-1 is an exceptional 
member of the Bcl2 family because of its non-Bcl2-homologous, extended N-terminus that is 
highly susceptible to various kinds of regulation due to the presence of 4 PEST regions 
(Proline/Glutamic acid/Serine/Threonine). In particular, phosphorylations on the Ser/Thr 
residues of these regions, differentially regulates the stability of Mcl-1 (Michels, Johnson et 
al. 2005, Thomas, Lam et al. 2010). While some phosphorylations are known to stabilize this 
protein, a double phosphorylation at Ser 159 and Thr 163 in response to UV, makes it labile. 
In this case, phosphorylation at Thr 163 is mediated by JNKs while Ser 159 is mediated by 
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GSK-3β - Glycogen Synthase Kinase-3β (Maurer, Charvet et al. 2006, Morel, Carlson et al. 
2009). Similarly, a triple phosphorylation of Ser 155/Ser 159/Thr 163 mediated by GSK-3β, 
also renders Mcl-1 unstable (Ding, He et al. 2007). Extrapolating this to our system, we can 
presume that a direct interaction of Mcl-1 with MKP1 facilitates the dephosphorylation of Mcl-
1 at these residues and keeps it stable. This argument is supported by the recent work of 
Nifousi and colleagues where Mcl-1 was shown to be de-phosphorylated at Thr 163/Ser 159 
by an interaction with a different phosphatase, PP2A (Nifoussi, Ratcliffe et al. 2014). We can 
check this hypothesis in our setup, by analyzing the phosphorylated forms of Mcl-1 in a co-
immunoprecipitation assay using MKP1 depleted cells, treated with proteasome inhibitor (to 
inhibit Mcl-1 degradation).  
Instead of a direct interaction, another possibility could be the existence of MKP1 in a 
complex with both JNK and Mcl-1. In this way, MKP1 inactivates JNK and subsequently 
inhibits the priming phosphorylation required for Mcl-1 degradation. Since JNK is a primary 
substrate of MKP1, this idea also seems conceivable. Infact, this is consistent with our 
findings, where JNK is phosphorylated in the absence of MKP1 (Appendix, Fig. 7.5). 
Whether this affects the phosphorylation and subsequent degradation of Mcl-1, is still to be 
determined. One approach would be to deplete cells of both JNK and MKP1, and check if 
this would rescue MKP1 knock-down induced Mcl-1 degradation. 
6.5 Chemosensitization with MKP1 inhibition  
Various cancers including pancreatic, ovarian, lung and breast have an over-expression of 
MKP1 (see 2.8) which make them resistant to a wide range of chemotherapeutic drugs. In 
such a scenario, down-regulation of this protein would prove beneficial during chemotherapy. 
Since many of these drugs target DNA replication, combining them with MKP1 inhibition 
which produced similar effects, seemed like an attractive idea for achieving 
chemosensitization. Exploiting this, we used MKP1 inhibitor, BCI, in combination with a 
chemotherapeutic, gemcitabine, and monitored the effects on replication fork kinetics. 
Indeed, in our experiments, the combination of drugs slowed down replication rates to a 
larger extent than the single treatments. Such a massive reduction in DNA synthesis can 
activate the S-phase checkpoint leading to a cell-cycle arrest until the damage is resolved. In 
case of an irreparable, overwhelming damage, cells initiate apoptosis by activating the ATM-
Chk2-p53 pathway (Karnitz, Flatten et al. 2005, Ewald, Sampath et al. 2008). Indeed, a long 
term proliferation assay (over a period of one week) using bright-field microscopy to quantify 
the cell confluence, can help analyze the rate of cellular survival after such a combined 
treatment. Since cancers mostly have deregulated checkpoint pathways, many-a-times, cells 
manage to escape the S-phase checkpoint and proceed prematurely to mitosis with an 
incompletely replicated genome. Under conditions where the mitotic checkpoint is also 
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defective, cells go into mitotic catastrophe. Even a prolonged arrest at mitosis can lead to 
this phenomenon (Castedo, Perfettini et al. 2004, Mansilla, Bataller et al. 2006, Vitale, 
Galluzzi et al. 2011). While our preliminary results with the combination of MKP1 inhibitor 
and gemcitabine need to be consolidated further; this kind of combination treatment might 
indeed be advantageous for patients having an over-expression of MKP1. 
Along this line, small molecules targeting MKP1 are being developed and tested in model 
systems. However, due to the structural similarity among the MKP family members, it is 
difficult to attain specificity towards any one protein. Often, most of the drugs target other 
closely related family members as well. Nonetheless, inhibiting more than one MKP might be 
favorable for the outcome of certain cancers which have a high expression of different MKPs.  
Some examples for MKP1 inhibitors include sanguinarine, NSC9537 and TPI-3, which show 
promising effects in in-vitro experiments. Of these, NSC9537 and TPI-3 seem to produce the 
best cytotoxic effects in cell culture systems (Nunes-Xavier, Roma-Mateo et al. 2011). To 
overcome the specificity problem, producing allosteric inhibitors (e.g. BCI for MKP1 and 
MKP3) which target a site other than the catalytic domain, seems like a worthy alternative for 
certain MKPs which rely on conformational changes for activation. Drugs targeting the kinase 
interaction motif at N- terminus which is required for substrate binding may also make the 
inhibition more specific. Apart from this, some agents like triptolide, a diterpenoid triepoxide, 
decrease the expression of MKP1 and have been shown to inhibit the proliferation of 
immortalized hippocampal cells (Koo, Kang et al. 2009). Triptolide was later shown to target 
a wide range of molecules including hsp70, Bax, Bcl-2, Mcl-1, and RNA polymerases which 
contributed to its effectiveness as an anti-cancer agent (R. 2014). While this was extremely 
encouraging, its poor solubility in water constrained its use in clinics. As an alternative, 
derivative of Triptolide, called Minnelide, has been reported to prevent tumor growth in 
mouse models of pancreatic cancer and osteosarcoma (Chugh, Sangwan et al. 2012, 
Banerjee, Thayanithy et al. 2013). Even though the involvement of MKP1 in this was 
undefined, considering its similarity to triptolide, one can imagine that it affects MKP1 
expression as well. While MKP1 inhibitors may have a positive role in the treatment of 
cancers, owing to the dual function of MKP1 as a tumor suppressor or an oncogene (see 
2.8), a major challenge still lies ahead before inhibitors are put forward for clinical trials.  
6.6 Conclusions: MKP1 in DNA replication, cellular survival and cancer 
Based on the results of this work, the function of MKP1 in DNA replication and survival can 
be summarized as follows: In an unperturbed cell cycle, MKP1 is required for inactivating the 
p38MAPK-MK2 and ATM-Chk2 pathway to maintain an optimal density of active forks 
progressing at normal speeds. This would be necessary to avoid the depletion of replication 
factors or nucleotides that might arise if too many origins fire or if a fork progresses too fast 
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(Mantiero, Mackenzie et al. 2011, Poli, Tsaponina et al. 2012, Zhong, Nellimoottil et al. 
2013). Additionally, MKP1 maintains stable levels of Cdc7, possibly to ensure complete 
genome replication by activating a sufficient number of origins. Thus, MKP1 is essential to 
shield the genome from spontaneously arising replicative stress. In an alternate pathway, 
MKP1 protects Mcl-1 from degradation, and promotes cellular survival.  
In the absence of MKP1, active ATM and MK2 promote replicative stress by altering fork 
dynamics and origin firing. This arrest in replication may lead to an accumulation of stalled 
forks that collapse over time, giving rise to irreparable DNA damage (Zeman and Cimprich 
2014). Furthermore, due to the loss of additional proteins, Cdc7 and Mcl-1, MKP1-depleted 
cells suffer overwhelming stress and succumb to cell death. If these damaged cells manage 
to enter mitosis with an incompletely replicated genome, mitotic catastrophe (i.e. cell death 
due to mitotic failure) can ensue. This safe-guarding nature of MKP1 makes it an attractive 
druggable target to be used in combination with chemotherapeutics, for the treatment of 
cancer.  





Figure 7.1 MK2 inhibition rescues the accumulation of phospho-H2AX (S139) upon MKP1 
inhibition.  
U2OS cells were exposed to 5 µM in the presence or absence of MK2 inhibitor (MK2III) for 24 h, and 




Figure 7.2 The loss of Chk1 phosphorylation upon MKP1 inhibition and Gemcitabine treatment 
is independent of ATR and Claspin. 
U2OS cells were treated with 5 µM BCI, 500 nM Gemcitabine or an equal volume of DMSO. Protein 
extracts were prepared after each of the indicated time points and subjected to an immunoblot 
analysis with the antibodies mentioned in the figure. Hsc70 served as a loading control.  
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Figure 7.3 Different antibodies to Cdc7 yield similar patterns upon MKP1 inhibition. 
U2OS cells were treated with 5 µM BCI, or an equal volume of DMSO. Protein extracts prepared after 
each of the indicated time points were subjected to an immunoblot analysis with the different 
antibodies mentioned in the figure. Cdc7 DCS341 was from abcam (ab10535), while Cdc7 SPM171 
was from Santa Cruz. β-Actin served as a loading control.  
 
 
Figure 7.4 Activation of p53 may be responsible for the loss of Cdc7 observed with MKP1 
inhibition. 
MiaPaCa-2, HCT116 p53 -/- and HCT116 p53 +/+ cells were treated with 5 µM BCI, or an equal 
volume of DMSO in the presence of a pan-caspase inhibitor Z-VAD-FMK for 4h. Cells were harvested 
for protein lysates after 4 h and an immunoblot analysis was done. Indicated antibodies were used. β-
Actin served as a loading control.  
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Figure 7.5 MKP1 knockdown leads to the activation of JNK. 
U2OS cells were reverse transfected with a non-targeting siRNA or siRNA specific to MKP1 
(designated as s4363, 10 nM) using lipofectamine and harvested after 48 h for immunoblot analysis. 













Figure 7.6 Plasmid maps of pCMV-DUSP1 and pcDNA3 
The plasmid maps of pCMV-DUSP1 and pCDNA3 used in the over expression experiments have 
been shown. Additional information about the purchase of plasmids is given in materials (see 3.11). 
pcDNA3 was purchased from Invitrogen, Life technologies and pCMV-DUSP1 was purchased from 
Origene. 
 




°C Degree Celsius 
9-1-1 Rad9-Hus1-Rad1 
53BP1 P53 binding protein 1 
µg  Microgram 
µL  Microliter 
µm Micrometer 
µM Micromolar 
AP-1 Activator protein 1 
APAF1 Apoptotic protease activating factor 1 
APC Anaphase promoting complex 
APS Ammonium persulfate 
ATF2 Activating transcription factor 2 
ATM Ataxia telangiectasia mutated 
ATP Adenosine triphosphate 
ATR ATM- and Rad3-related 
ATRIP ATR interacting protein 
Bak Bcl-2 homologous antagonist/killer 
Bax Bcl-2-associated X protein 
BCA Bicinchoninic acid 
Bcl-2 B-cell lymphoma 2 
Bcl-w Bcl-2-like protein 2 
Bcl-xL B-cell lymphoma-extra large 
BH Bcl2 homology 
BLM Bloom syndrome 
BRCA1 Breast cancer susceptibility gene 1 
BRCA2 Breast cancer susceptibility gene 2 
BrdU Bromodeoxyuridine 
BSA Bovine serum albumin 
CAD Caspase activated DNase 
CAK Cdk activating kinase 
CAF1 Chromatin assembly factor 1 
caspases Cysteine aspartic proteases 
cDNA Complementary DNA 
Cdk2 Cyclin dependent kinase 2 
Cdc6 Cell division cycle 6 
Cdc7 Cell division cycle 7 
Cdc25 Cell division cycle 25 
Cdc45 Cell division cycle 45 
Cdt1 Chromatin licensing and DNA replication factor 1 
Chk1 Checkpoint kinase 1 
Chk2 Checkpoint kinase 2 
Chk3 Checkpoint kinase 3 
CldU Chlorodeoxyuridine 
cm Centimeter 
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CoIP Co-immunoprecipitation 
Crm1 Chromosome region maintenance 1 
ddNTP Di-deoxy nucleoside triphosphate 
dNTP Deoxy nucleoside triphosphate 
DDR DNA damage response 
DHFR Dihydrofolate reductase 
DMEM Dulbecco's modified eagle's medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DSB Double strand break 
EDTA Ethylene diamine tetraacetic acid 
EGFR Epidermal growth factor receptor 
ERK Extracellular-signal-regulated kinases 
EtOH Ethanol 
EXO-11 Exonuclease 11 
FANCJ Fanconi anemia group J 
Fas-L Fas ligand 
FDA Food and drug administration 
FCS Fetal calf serum 
G1 Gap1 
G2 Gap2 
GINS Go, Ichi, Nii, and San 
Glu Glutamine 
GSK-3β Glycogen synthase kinase 3 
h Hour 
H2A Histone 2A 
H2AX Histone 2AX 
HR Homologous recombination 
HCl Hydrochloric acid 
HRP Horse radish peroxidase 
Hsp27 Heat shock protein 27 
IdU Iododeoxyuridine 
IgG Immunoglobulin G 
Inh Inhibitor 
JNK c-Jun N-terminal kinase 
kDa Kilodalton 
KIU Kallikrein inactivator unit 
M Molar 
M Mitotic  
MAPK Mitogen activated protein kinase 
MAPKK/MKK MAPK kinase 
MAPKKK/ MKKK MAPK kinase kinase 
Mcl-1 Myeloid cell leukemia 
MCS Multiple cloning site 
MCM Minichromosome maintenance 
MDC-1 Mediator of DNA damage checkpoint protein 1 
MEFs Mouse embryonic fibroblasts 
MetOH Methanol 
mg Milligram 
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min Minute 
MK2 MAPK activated protein kinase 2 
MKP MAPK phosphatase 
mL Milliliter 
mM Millimolar 
MOMP Mitochondrial outer membrane permeabilization 
MRE11 Meiotic recombination 11 
MRN Mre11 Rad50 Nbs1 
mRNA Messenger RNA 
MSK1 Mitogen- and stress-activated protein kinase 




NP-40 Nonidet P-40 substitute 
ns Non-significant 
NSCLC Non-small cell lung carcinoma 
OMM Outer mitochondrial membrane 
ORC Origin recognition complex 
Ori Origin 
p Phospho 
PARP-1 Poly (ADP-ribose) polymerase 1 
PBS Phosphate buffer saline 
PCNA Proliferating cell nuclear antigen 
PCR Polymerase chain reaction 
PGS Protein G sepharose 
PIKK Phosphatidylinositol 3-kinase related kinase 
Plk1 Polo-like Kinase1 
Pol Polymerase 
PP1  Protein phosphatase 1 
PP2A Protein phosphatase 2A 
Pre-RC Pre- replicative complex 
qRT-PCR Quantitative reverse transcriptase PCR 
RFC Replication factor C 
RNA Ribonucleic acid 
RPA Replication protein A 
rpm Revolutions per min 
RT Room temperature 
S Synthesis 
SAPK Stress activated protein kinase 
SCF Skp, Cullin, F-box 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
siRNA Small interfering RNA 
ssDNA Single strand DNA 
TBS-T Tris buffer saline with tween 
TEMED Tetramethylethylenediamine 
Tim Timeless 
Tipin Timeless interacting protein 
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TLS Translesion synthesis 
TNF-α Tumor necrosis factor α 
TOPBP1 Topoisomerase (DNA) II binding protein 1 
Tris Trisamine 
UV Ultraviolet 
Wip1 Wild-type P53-induced phosphatase 1 
WRN Werner 
wt Wildtype 
YT Yeast tryptone 
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